Sabra Health Care REIT (SBRA) 10-Q 3 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 01, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Sabra Health Care REIT, Inc.
Entity Central Index Key	1,492,298
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		65,273,218

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets
Real estate investments, net of accumulated depreciation of $242,630 and $237,841 as of March 31, 2016 and December 31, 2015, respectively	$ 1,923,773	$ 2,039,616
Loans receivable and other investments, net	297,508	300,177
Cash and cash equivalents	9,133	7,434
Restricted cash	8,773	9,813
Assets held for sale	75,450	0
Prepaid expenses, deferred financing costs and other assets, net	119,519	111,797
Total assets	2,434,156	2,468,837
Liabilities
Mortgage notes, net	175,045	174,846
Revolving credit facility	198,000	255,000
Term loans, net	338,629	264,229
Senior unsecured notes, net	686,336	685,704
Liabilities held for sale	340	0
Accounts payable and accrued liabilities	28,308	35,182
Total liabilities	$ 1,426,658	$ 1,414,961
Commitments and contingencies (Note 12)
Equity
Preferred stock, $.01 par value; 10,000,000 shares authorized, 5,750,000 shares issued and outstanding as of March 31, 2016 and December 31, 2015	$ 58	$ 58
Common stock, $.01 par value; 125,000,000 shares authorized, 65,273,218 and 65,182,335 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	653	652
Additional paid-in capital	1,203,390	1,202,541
Cumulative distributions in excess of net income	(187,279)	(142,148)
Accumulated other comprehensive loss	(9,398)	(7,333)
Total Sabra Health Care REIT, Inc. stockholders’ equity	1,007,424	1,053,770
Noncontrolling interests	74	106
Total equity	1,007,498	1,053,876
Total liabilities and equity	$ 2,434,156	$ 2,468,837

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets
Accumulated depreciation	$ 242,630	$ 237,841
Equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	5,750,000	5,750,000
Preferred stock, shares outstanding (in shares)	5,750,000	5,750,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	65,273,218	65,182,335
Common stock, shares outstanding (in shares)	65,273,218	65,182,335

Condensed Consolidated Statemen

Condensed Consolidated Statements of (Loss) Income (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Rental income	$ 55,312	$ 49,505
Interest and other income	5,332	5,385
Resident fees and services	1,915	682
Total revenues	62,559	55,572
Expenses:
Depreciation and amortization	17,766	14,150
Interest	16,918	13,880
Operating expenses	1,412	498
General and administrative	4,714	6,361
Provision for doubtful accounts and loan losses	2,523	1,144
Impairment of real estate	29,811	0
Total expenses	73,144	36,033
Other expense:
Loss on extinguishment of debt	(556)	0
Other expense	0	(100)
Net loss on sale of real estate	(4,602)	0
Total other income (expense)	(5,158)	(100)
Net (loss) income	(15,743)	19,439
Net loss attributable to noncontrolling interests	32	11
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(15,711)	19,450
Preferred stock dividends	(2,561)	(2,561)
Net (loss) income attributable to common stockholders	$ (18,272)	$ 16,889
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.28)	$ 0.29
Diluted common share (in dollars per share)	$ (0.28)	$ 0.28
Weighted-average number of common shares outstanding, basic (in shares)	65,248,203	59,185,225
Weighted-average number of common shares outstanding, diluted (in shares)	65,248,203	59,559,253

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (15,743)	$ 19,439
Other comprehensive income (loss):
Foreign currency translation	(573)	0
Unrealized loss on cash flow hedges	(1,492)	(1,545)
Total other comprehensive loss	(2,065)	(1,545)
Comprehensive (loss) income	(17,808)	17,894
Comprehensive loss attributable to noncontrolling interest	32	11
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	$ (17,776)	$ 17,905

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Equity (unaudited) - USD ($) $ in Thousands	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Cumulative Distributions in Excess of Net Income [Member]	Accumulated Other Comprehensive Loss [Member]	Total Stockholders' Equity [Member]	Noncontrolling Interest [Member]	Common Stock [Member]	Common Stock [Member]Common Stock [Member]	Common Stock [Member]Additional Paid-in Capital [Member]	Common Stock [Member]Total Stockholders' Equity [Member]
Beginning balance (in shares) at Dec. 31, 2014		5,750,000	59,047,001
Beginning balance at Dec. 31, 2014	$ 941,823	$ 58	$ 590	$ 1,053,601	$ (110,841)	$ (1,542)	$ 941,866	$ (43)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	19,439				19,450		19,450	(11)
Other comprehensive loss	(1,545)					(1,545)	(1,545)
Amortization of stock-based compensation	3,023			3,023			3,023
Common stock issuance, net (in shares)										187,055
Common stock issuance, net									$ (4,809)	$ 2	$ (4,811)	$ (4,809)
Preferred dividends	(2,561)				(2,561)		(2,561)
Common dividends	(23,216)				(23,216)		(23,216)
Ending balance (in shares) at Mar. 31, 2015		5,750,000	59,234,056
Ending balance at Mar. 31, 2015	932,154	$ 58	$ 592	1,051,813	(117,168)	(3,087)	932,208	(54)
Beginning balance (in shares) at Dec. 31, 2015		5,750,000	65,182,335
Beginning balance at Dec. 31, 2015	1,053,876	$ 58	$ 652	1,202,541	(142,148)	(7,333)	1,053,770	106
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(15,743)				(15,711)			(32)
Other comprehensive loss	(2,065)					(2,065)	(2,065)
Amortization of stock-based compensation	1,938			1,938			1,938
Common stock issuance, net (in shares)										90,883
Common stock issuance, net									$ (1,088)	$ 1	$ (1,089)	$ (1,088)
Preferred dividends	(2,561)				(2,561)		(2,561)
Common dividends	(26,859)				(26,859)		(26,859)
Ending balance (in shares) at Mar. 31, 2016		5,750,000	65,273,218
Ending balance at Mar. 31, 2016	$ 1,007,498	$ 58	$ 653	$ 1,203,390	$ (187,279)	$ (9,398)	$ 1,007,424	$ 74

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Equity (unaudited) (Parenthetical) - $ / shares	Feb. 03, 2016	Mar. 31, 2016	Mar. 31, 2015
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 0.41	$ 0.41	$ 0.39

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (15,743,000)	$ 19,439,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,766,000	14,150,000
Non-cash interest income adjustments	222,000	113,000
Amortization of deferred financing costs	1,221,000	1,261,000
Stock-based compensation expense	1,818,000	2,918,000
Amortization of debt discount	27,000	25,000
Loss on extinguishment of debt	556,000	0
Straight-line rental income adjustments	(5,593,000)	(5,656,000)
Provision for doubtful accounts and loan losses	2,523,000	1,144,000
Change in fair value of contingent consideration	0	100,000
Net loss on sales of real estate	4,602,000	0
Impairment of real estate	29,811,000	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(5,900,000)	(3,206,000)
Accounts payable and accrued liabilities	(5,430,000)	(4,988,000)
Restricted cash	(1,154,000)	(599,000)
Net cash provided by operating activities	24,726,000	24,701,000
Cash flows from investing activities:
Origination and fundings of loans receivable	(5,850,000)	(7,303,000)
Origination and fundings of preferred equity investments	(984,000)	(311,000)
Additions to real estate	(474,000)	(675,000)
Repayment of loans receivable	8,874,000	2,052,000
Net proceeds from the sale of real estate	398,000	0
Net cash provided by (used in) investing activities	1,964,000	(6,237,000)
Cash flows from financing activities:
Net repayments of revolving credit facility	(57,000,000)	(42,000,000)
Proceeds from term loans	69,360,000	0
Principal payments on mortgage notes	(1,022,000)	(697,000)
Payments of deferred financing costs	(5,885,000)	(130,000)
Issuance of common stock	(1,274,000)	(7,587,000)
Dividends paid on common and preferred stock	(29,301,000)	(25,672,000)
Net cash (used in) provided by financing activities	(25,122,000)	(76,086,000)
Net increase (decrease) in cash and cash equivalents	1,568,000	(57,622,000)
Effect of foreign currency translation on cash and cash equivalents	131,000	0
Cash and cash equivalents, beginning of period	7,434,000	61,793,000
Cash and cash equivalents, end of period	9,133,000	4,171,000
Supplemental disclosure of cash flow information:
Interest paid	$ 19,459,000	$ 16,761,000

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Overview Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra's separation from Sun (the "Separation Date"). Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the United States and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and Sabra's wholly owned subsidiaries are currently the only limited partners, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing facilities, acute care hospitals, investments in loans receivable and preferred equity investments.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2016 and December 31, 2015 and for the periods ended March 31, 2016 and 2015. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 . For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s 2015 Annual Report on Form 10-K filed with the SEC. GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity's activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity's activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity's activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity's equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity's economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2016 , the Company determined it was the primary beneficiary of two senior housing facilities and has consolidated the operations of the facilities in the accompanying condensed consolidated financial statements. As of March 31, 2016 , the Company determined that operations of the facilities were not material to the Company’s results of operations, financial condition or cash flows. As it relates to investments in loans, in addition to the Company's assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine if the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower's expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2016 , none of the Company's investments in loans are accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners' rights and their impact on the presumption of control of the limited partnership by any single partner. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners, the sole general partner increases or decreases its ownership of limited partnership interests, or there is an increase or decrease in the number of outstanding limited partnership interests. The Company also applies this guidance to managing member interests in limited liability companies. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Reclassifications Certain amounts in the Company’s condensed consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated balance sheets and condensed consolidated statements of (loss) income. As of December 31, 2015, there was $17.3 million of deferred financing costs related to the Company's mortgage notes, term loans and senior unsecured notes that were previously reported within “prepaid expenses, deferred financing costs and other assets, net” that were reclassified in accordance with ASU 2015-03 to their respective debt liability financial statement line items on the Company’s condensed consolidated balance sheet. Recently Issued Accounting Standards Update In January 2016, the FASB issued ASU 2016-01, Financial Instruments–Overall (Subtopic 825-10) (“ASU 2016-01”). ASU 2016-01 updates guidance related to recognition and measurement of financial assets and financial liabilities. ASU 2016-01 requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in ASU 2016-01 also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in ASU 2016-01 eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. ASU 2016-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting, however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In March 2016, the FASB issued ASU 2016-07, Equity Method and Joint Ventures (Topic 323) (“ASU 2016-07”). ASU 2016-07 simplifies the accounting for equity method investments. ASU 2016-07 eliminates the requirement in Topic 323 that an entity retroactively adopt the equity method of accounting if an investment qualifies for use of the equity method as a result of an increase in the level of ownership or degree of influence. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. ASU 2016-07 is effective for fiscal years and interim periods within those years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the amendments in ASU 2016-09 eliminate the guidance in Topic 718 that was indefinitely deferred shortly after the issuance of FASB Statement No. 123 (revised 2004), Share-Based Payment. ASU 2016-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

REAL ESTATE PROPERTIES HELD FOR

REAL ESTATE PROPERTIES HELD FOR INVESTMENT	3 Months Ended
	Mar. 31, 2016
Real Estate Investments, Net [Abstract]
REAL ESTATE PROPERTIES HELD FOR INVESTMENT	REAL ESTATE PROPERTIES HELD FOR INVESTMENT The Company’s real estate properties held for investment (excluding properties classified as held for sale as of March 31, 2016 ) consisted of the following (dollars in thousands): As of March 31, 2016 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 102 11,535 $ 1,043,771 $ (180,184 ) $ 863,587 Senior Housing 75 6,727 1,060,635 (53,205 ) 1,007,430 Acute Care Hospital 1 70 61,640 (9,002 ) 52,638 178 18,332 2,166,046 (242,391 ) 1,923,655 Corporate Level 357 (239 ) 118 $ 2,166,403 $ (242,630 ) $ 1,923,773 As of December 31, 2015 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 103 11,515 $ 1,051,189 $ (174,662 ) $ 876,527 Senior Housing 75 6,710 1,050,162 (45,800 ) 1,004,362 Acute Care Hospitals 2 124 175,807 (17,127 ) 158,680 180 18,349 2,277,158 (237,589 ) 2,039,569 Corporate Level 299 (252 ) 47 $ 2,277,457 $ (237,841 ) $ 2,039,616 March 31, 2016 December 31, 2015 Building and improvements $ 1,863,888 $ 1,954,129 Furniture and equipment 82,110 97,840 Land improvements 3,811 3,594 Land 216,594 221,894 2,166,403 2,277,457 Accumulated depreciation (242,630 ) (237,841 ) $ 1,923,773 $ 2,039,616 Contingent Consideration Arrangements In connection with four of its real estate acquisitions, the Company entered into contingent consideration arrangements. Under the contingent consideration arrangements, the Company may pay out additional amounts based on incremental value created through the improvement of operations of the acquired facility (a contingent consideration liability) or may be entitled to receive a portion of the original purchase price of the acquired facility if the facility does not meet certain performance hurdles (a contingent consideration asset). The estimated value of the contingent consideration liabilities at the time of purchase was $3.2 million . The estimated value of the contingent consideration asset at the time of purchase was $0. The contingent consideration amounts would be determined based on portfolio performance and the tenant achieving certain performance hurdles during 2016 through 2018. To determine the value of the contingent consideration, the Company used significant inputs not observable in the market to estimate the contingent consideration, made assumptions regarding the probability of the portfolio achieving the incremental value and then applied an appropriate discount rate. As of March 31, 2016 , based on the potential future performance of these facilities, the contingent consideration liabilities had an estimated value of $2.7 million and the contingent consideration asset had an estimated value of $0.3 million ; these amounts are included in accounts payable and accrued liabilities and prepaid expenses, deferred financing costs and other assets, net, respectively, in the accompanying condensed consolidated balance sheet. During the three months ended March 31, 2016 , the Company did no t record any adjustments to its contingent consideration liabilities or asset. Operating Leases As of March 31, 2016 , all of the Company’s real estate properties were leased under triple-net operating leases with expirations ranging from one to 17 years. As of March 31, 2016 , the leases had a weighted-average remaining term of 10 years. The leases include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. In addition, the Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheets and totaled $1.4 million as of March 31, 2016 and $1.3 million as of December 31, 2015 . As of March 31, 2016 , the Company had a $3.5 million reserve for unpaid cash rents and a $5.5 million reserve associated with accumulated straight-line rental income. As of December 31, 2015 , the Company had a $3.5 million reserve for unpaid cash rents and a $5.3 million reserve associated with accumulated straight-line rental income. As of March 31, 2016 , the Company's three largest tenants, Genesis, Holiday and NMS Healthcare, represented 33.9% , 16.7% and 10.4% , respectively, of the Company's annualized revenues. Other than these three tenants, none of the Company’s tenants individually represented 10% or more of the Company’s annualized revenues as of March 31, 2016 . The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. Because formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenants’ ability to pay their rent obligations to the Company) is the tenants’ lease coverage ratios. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the facility level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry's operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenants’ ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company. As of March 31, 2016 , the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases was as follows (in thousands): April 1, 2016 through December 31, 2016 $ 187,182 2017 207,388 2018 212,874 2019 219,026 2020 225,025 Thereafter 1,165,259 $ 2,216,754

ASSETS HELD FOR SALE AND DISPOS

ASSETS HELD FOR SALE AND DISPOSITIONS	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
ASSETS HELD FOR SALE AND DISPOSITIONS	ASSETS HELD FOR SALE AND DISPOSITIONS Asset Held for Sale As of March 31, 2016 , the Company determined that one acute care hospital met the criteria to be classified as held for sale. As a result of this determination, the Company adjusted the net book value of this investment to its fair value less costs to sell of $75.1 million , resulting in an impairment loss of $29.8 million . Dispositions During the three months ended March 31, 2016 , the Company completed the sale of one skilled nursing facility for consideration of $0.4 million after selling expenses of $0.1 million . The carrying value of the assets and liabilities of this facility was $5.0 million , which resulted in a $4.6 million loss. The Company sold no facilities during the three months ended March 31, 2015. During the three months ended March 31, 2016 and 2015, the Company recognized $(1.2) million (excluding the loss on sale and real estate impairment charge) and $1.0 million of net (loss) income, respectively, from these facilities. Neither the determination of the held for sale classification nor the sale of the facility above represent a strategic shift that has or will have a major effect on the Company's operations and financial results and therefore the results of operations attributable to these facilities have remained in continuing operations.

LOANS RECEIVABLE AND OTHER INVE

LOANS RECEIVABLE AND OTHER INVESTMENTS	3 Months Ended
	Mar. 31, 2016
Loans Receivable and Other Investments [Abstract]
LOANS RECEIVABLE AND OTHER INVESTMENTS	LOANS RECEIVABLE AND OTHER INVESTMENTS As of March 31, 2016 and December 31, 2015 , the Company’s loans receivable and other investments consisted of the following (dollars in thousands): Investment Quantity Facility Type Principal Balance / Amount Funded as of March 31, 2016 Book Value as of March 31, 2016 Book Value as of Weighted Average Contractual Interest Rate / Rate of Return Weighted Average Annualized Effective Interest Rate / Rate of Return Maturity Dates Loans Receivable: Mortgage 8 Skilled Nursing / Senior Housing / Acute Care Hospital $ 166,610 $ 166,795 $ 166,277 8.4 % 8.2 % 6/30/16- 4/30/18 Construction 4 Acute Care Hospital / Senior Housing 75,380 75,526 75,201 14.0 % 13.9 % 9/30/16 - 3/31/21 Mezzanine 1 Skilled Nursing / Senior Housing 9,640 9,672 15,613 11.0 % 10.8 % 08/31/17 Pre-development 3 Senior Housing 3,767 3,839 3,768 9.0 % 7.7 % 1/28/17 - 9/09/17 Debtor-in-possession 1 Acute Care Hospital 16,418 16,418 13,625 5.0 % 5.0 % NA 17 271,815 272,250 274,484 9.8 % 9.7 % Loan loss reserve — (6,700 ) (4,300 ) $ 271,815 $ 265,550 $ 270,184 Other Investments: Preferred Equity 10 Skilled Nursing / Senior Housing 31,608 31,958 29,993 13.1 % 13.1 % N/A Total 27 $ 303,423 $ 297,508 $ 300,177 10.1 % 10.1 % As of March 31, 2016 , the Company considered two loan receivable investments with principal balances totaling $29.8 million to be impaired and recorded a $2.3 million provision for loan losses related to these loans during the three months ended March 31, 2016. During the three months ended March 31, 2016 , the Company recorded a $0.1 million provision for portfolio-based loan losses. The Company's specific loan loss reserve and portfolio-based loan loss reserve were $4.8 million and $1.9 million , respectively, as of March 31, 2016. There was no specific loan loss reserve or portfolio-based loan loss reserve as of March 31, 2015. In addition, as of March 31, 2016 and December 31, 2015, two loan receivable investments totaling $123.5 million were on nonaccrual status and one loan receivable investment of $60.9 million was over 90 days past due but on accrual status.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
DEBT	DEBT Mortgage Indebtedness The Company’s mortgage notes payable consist of the following (dollars in thousands): Interest Rate Type Principal Balance as of (1) Principal Balance as of (1) Weighted Average (2) Maturity Date Fixed Rate $ 178,017 $ 177,850 4.01 % December 2021 - (1) Principal balance does not include deferred financing costs of $ 3.0 million as of March 31, 2016 and December 31, 2015. (2) Weighted average effective rate includes private mortgage insurance. Senior Unsecured Notes The Company’s senior unsecured notes consist of the following (dollars in thousands): Principal Balance as of Title Maturity Date March 31, 2016 (1) December 31, 2015 (1) 5.5% senior unsecured notes due 2021 (“2021 Notes”) February 1, 2021 $ 500,000 $ 500,000 5.375% senior unsecured notes due 2023 (“2023 Notes”) June 1, 2023 200,000 200,000 $ 700,000 $ 700,000 (1) Principal balance does not include discount of $ 0.6 million as of March 31, 2016 and December 31, 2015 and also excludes deferred financing costs of $13.1 million and $13.7 million as of March 31, 2016 and December 31, 2015, respectively. The 2021 Notes and the 2023 Notes (collectively, the “Senior Notes”) were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”). The 2021 Notes accrue interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year and the 2023 Notes accrue interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year. The obligations under the Senior Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and certain of Sabra’s other existing and, subject to certain exceptions, future material subsidiaries; provided, however, that such guarantees are subject to release under certain customary circumstances. See Note 11, “Summarized Condensed Consolidating Information” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees. The indentures governing the Senior Notes (the “Senior Notes Indentures”) include customary events of default and require us to comply with specified restrictive covenants. As of March 31, 2016 , the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures. Revolving Credit Facility and Term Loans On September 10, 2014, the Operating Partnership entered into an unsecured revolving credit facility (the “Prior Revolving Credit Facility”) that provided for a borrowing capacity of $650.0 million and provided an accordion feature allowing for an additional $100.0 million of capacity, subject to terms and conditions. On October 10, 2014, the Operating Partnership converted $200.0 million of the outstanding borrowings under the Prior Revolving Credit Facility to a term loan. Concurrent with the term loan conversion, the Company entered into a five -year interest rate cap contract that caps LIBOR at 2.0% . Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to an applicable percentage plus, at the Operating Partnership's option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5% , (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (referred to as the “Base Rate”). The applicable percentage for borrowings varied based on the Consolidated Leverage Ratio, as defined in the credit agreement for the Prior Revolving Credit Facility, and ranged from 2.00% to 2.60% per annum for LIBOR based borrowings and 1.00% to 1.60% per annum for borrowings at the Base Rate. As of December 31, 2015, the interest rate on the Prior Revolving Credit Facility was 3.03% . In addition, the Operating Partnership was required to pay an unused fee to the lenders equal to 0.25% or 0.35% per annum based on the amount of unused borrowings under the Prior Revolving Credit Facility. On June 10, 2015, Sabra Canadian Holdings, LLC, a wholly-owned subsidiary of the Company, entered into a new Canadian dollar denominated term loan of CAD $90.0 million (U.S. $73.2 million ) (the "Prior Canadian Term Loan") that bore a variable interest rate of the Canadian Dollar Offer Rate (“CDOR”) plus 2.00% - 2.60% depending on the Company's consolidated leverage ratio. Concurrently with entering into the Prior Canadian Term Loan, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for this term loan at 1.59% . In addition, the Prior Canadian Term Loan was designated as a net investment hedge (see Note 7, “Derivative and Hedging Instruments” for further information). On January 14, 2016, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), entered into a third amended and restated unsecured credit facility (the “Credit Facility”). The Credit Facility amends and restates the a Prior Revolving Credit Facility and replaces the Prior Canadian Term Loan. The Credit Facility includes a revolving credit facility (the “Revolving Credit Facility”) and U.S. dollar and Canadian dollar term loans (collectively, the “Term Loans”). The Revolving Credit Facility provides for a borrowing capacity of $500.0 million and, in addition, increases the Company's U.S. dollar and Canadian dollar term loans to $245.0 million and CAD $125.0 million , respectively. Further, up to $125.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $1.25 billion , subject to terms and conditions. In addition, the Canadian dollar term loan was re-designated as a net investment hedge (see Note 7, “Derivative and Hedging Instruments” for further information). The Revolving Credit Facility has a maturity date of January 14, 2020, and includes two six -month extension options. The Term Loans have a maturity date of January 14, 2021. As of March 31, 2016 , there was $198.0 million outstanding under the Revolving Credit Facility and $302.0 million available for borrowing. Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable percentage plus, at the Operating Partnership's option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5% , (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the "Base Rate"). The applicable percentage for borrowings will vary based on the Consolidated Leverage Ratio, as defined in the credit agreement, and will range from 1.80% to 2.40% per annum for LIBOR based borrowings and 0.80% to 1.40% per annum for borrowings at the Base Rate. As of March 31, 2016 , the interest rate on the Revolving Credit Facility was 2.84% . In addition, the Operating Partnership pays an unused facility fee to the lenders equal to 0.25% or 0.30% per annum, which is determined by usage under the Revolving Credit Facility. During the three months ended March 31, 2016 , the Company incurred $1.5 million in interest expense on amounts outstanding under the Revolving Credit Facility and $0.2 million of unused facility fees. The U.S. dollar term loan bears interest on the outstanding principal amount at a rate equal to an applicable percentage plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The applicable percentage for borrowings will vary based on the Consolidated Leverage Ratio, as defined in the credit agreement, and will range from 1.75% to 2.35% per annum for LIBOR based borrowings and 0.75% to 1.35% per annum for borrowings at the Base Rate. The Canadian dollar term loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offer Rate (“CDOR”) plus 1.75% to 2.35% depending on the Consolidated Leverage Ratio. In the event that Sabra achieves investment grade ratings from at least two of S&P, Moody’s and/or Fitch, the Operating Partnership can elect to reduce the applicable percentage for LIBOR or Base Rate borrowings. If the Operating Partnership makes this election, the applicable percentage for borrowings will vary based on the Debt Ratings at each Pricing Level, as defined in the credit agreement, and will range from 0.90% to 1.70% per annum for LIBOR based borrowings under the Revolving Credit Facility, 1.00% to 1.95% per annum for LIBOR or CDOR based borrowings under the Term Loans, 0.00% to 0.70% per annum for borrowings at the Base Rate under the Revolving Credit Facility, and 0.00% to 0.95% per annum for borrowings at the Base Rate under the U.S. dollar term loan. In addition, should the Operating Partnership elect this option, the unused fee will no longer apply and a facility fee ranging between 0.125% and 0.300% per annum will take effect based on the borrowing capacity regardless of amounts outstanding under the Revolving Credit Facility. The obligations of the Borrowers under the Credit Facility are guaranteed by Sabra and certain subsidiaries of Sabra. The Credit Facility contains customary covenants that include restrictions or limitations on the ability to make acquisitions and other investments, pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Facility also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio and a minimum tangible net worth requirement. As of March 31, 2016 , the Company was in compliance with all applicable financial covenants under the Credit Facility. Interest Expense During the three months ended March 31, 2016 and 2015, the Company incurred interest expense of $16.9 million and $13.9 million , respectively. Included in interest expense for the three months ended March 31, 2016 and 2015 was $1.2 million and $1.3 million , respectively, of deferred financing costs amortization. As of March 31, 2016 and December 31, 2015 , the Company had $9.5 million and $ 13.3 million , respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets. Maturities The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2016 (in thousands): Mortgage Indebtedness Revolving Credit Facility (1) Term Loans Senior Notes Total April 1, 2016 through December 31, 2016 $ 3,139 $ — $ — $ — $ 3,139 2017 4,310 — — — 4,310 2018 4,458 — — — 4,458 2019 4,612 — — — 4,612 2020 4,770 198,000 — — 202,770 Thereafter 156,728 — 341,387 700,000 1,198,115 Total Principal Balance 178,017 198,000 341,387 700,000 1,417,404 Discount — — — (598 ) (598 ) Deferred financing costs (2,972 ) — (2,758 ) (13,066 ) (18,796 ) Total Debt, net $ 175,045 $ 198,000 $ 338,629 $ 686,336 $ 1,398,010 (1) Revolving Credit Facility is subject to two six-month extension options.

DERIVATIVE AND HEDGING INSTRUME

DERIVATIVE AND HEDGING INSTRUMENTS	3 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE AND HEDGING INSTRUMENTS	DERIVATIVE AND HEDGING INSTRUMENTS The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings. Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes. Cash Flow Hedges The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and caps as part of its interest rate risk management strategy. The notional value of the Company's interest rate cap was $200.0 million as of both March 31, 2016 and December 31, 2015 . The notional value of the Company's interest rate swap was CAD $90.0 million as of both March 31, 2016 and December 31, 2015 (U.S. $69.4 million and U.S. $64.9 million as of March 31, 2016 and December 31, 2015, respectively). Approximately $1.3 million of losses, which are included in accumulated other comprehensive loss, as of March 31, 2016 , are expected to be reclassified into earnings in the next 12 months. Net Investment Hedges The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments. The notional value of these contracts were CAD $56.3 million as of March 31, 2016 and December 31, 2015 (U.S. $43.4 million and U.S. $40.6 million as of March 31, 2016 and December 31, 2015 , respectively). The Company also holds a CAD $125.0 million (U.S. $96.4 million as of March 31, 2016) term loan which was designated as a net investment hedge. The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Maturity Dates Type Designation Count Fair Value Balance Sheet Location Assets: Interest rate cap Cash Flow 1 $ 670 $ 1,695 2019 Prepaid expenses, deferred financing costs and other assets, net Cross currency interest rate swaps Net Investment 2 2,838 5,392 2025 Prepaid expenses, deferred financing costs and other assets, net $ 3,508 $ 7,087 Liabilities: Interest rate swap Cash Flow 1 $ 1,989 $ 1,468 2020 Accounts payable and accrued liabilities CAD Term Loan Net Investment 1 96,388 64,890 2020 Term loans, net $ 98,377 $ 66,358 The following presents the effect of the Company’s derivative financial instruments on the condensed consolidated statements of (loss) income and the condensed consolidated statements of equity for the three months ended March 31, 2016 : Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion) Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion) Income Statement Location Three Months Ended March 31, 2016 2015 2016 2015 Cash Flow Hedges: Interest Rate Products $ (1,540 ) $ (1,545 ) $ (173 ) $ — Interest Expense Net Investment Hedges: Foreign Currency Products (2,503 ) — — — N/A CAD Term Loan 7,138 — — — N/A $ 3,095 $ (1,545 ) $ (173 ) $ — During the three months ended March 31, 2016 and 2015, the Company recorded no hedge ineffectiveness in the condensed consolidated statements of (loss) income. Offsetting Derivatives The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2016 and December 31, 2015: As of March 31, 2016 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 3,508 $ — $ 3,508 $ (1,430 ) $ — $ 2,078 Offsetting Liabilities: Derivatives $ 1,989 $ — $ 1,989 $ (1,430 ) $ — $ 559 As of December 31, 2015 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 7,087 $ — $ 7,087 $ (1,468 ) $ — $ 5,619 Offsetting Liabilities: Derivatives $ 1,468 $ — $ 1,468 $ (1,468 ) $ — $ — Credit-risk-related Contingent Features The Company has agreements with each of its derivative counterparties that contain a provision where if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then the Company could also be declared in default on its derivative obligations. As of March 31, 2016 , the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $1.1 million . As of March 31, 2016 , the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at March 31, 2016 , it could have been required to settle its obligations under the agreements at their termination value of $1.1 million .

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE DISCLOSURES	FAIR VALUE DISCLOSURES The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable : These instruments are presented in the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair value of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs. Preferred equity investments : These instruments are presented in the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair value of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs. Derivative instruments : The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate cap, interest rate swap and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which includes forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in level 2 of the fair value hierarchy. Senior Notes : These instruments are presented in the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums (discounts) and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2 inputs. Mortgage indebtedness : These instruments are presented in the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums (discounts) and not at fair value. The fair values of the Company’s mortgage notes payable were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs. The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2016 and December 31, 2015 whose carrying amounts do not approximate their fair value (in thousands): March 31, 2016 December 31, 2015 Carrying Amount (1) Face (2) Fair Value Carrying (1) Face (2) Fair Value Financial assets: Loans receivable $ 272,250 $ 271,815 $ 279,112 $ 270,184 $ 273,811 $ 274,628 Preferred equity investments 31,958 31,608 33,719 29,993 29,643 30,838 Financial liabilities: Senior Notes 686,336 700,000 697,250 685,704 700,000 718,500 Mortgage indebtedness 175,045 178,017 169,579 174,846 177,850 165,296 (1) Carrying amounts represent the book value of financial instruments and are net of unamortized premiums (discounts) and deferred financing costs. (2) Face value represents amounts contractually due under the terms of the respective agreements. The Company determined the fair value of financial instruments as of March 31, 2016 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Financial assets: Loans receivable $ 279,112 $ — $ — $ 279,112 Preferred equity investments 33,719 — — 33,719 Financial liabilities: Senior Notes 697,250 — 697,250 — Mortgage indebtedness 169,579 — — 169,579 Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different. During the three months ended March 31, 2016 , the Company recorded the following amounts measured at fair value (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Recurring Basis: Financial assets: Interest rate cap $ 670 $ — $ 670 $ — Cross currency swap 2,838 — 2,838 — Contingent consideration asset 350 — — 350 Financial liabilities: Contingent consideration liability 2,700 — — 2,700 Interest rate swap 1,989 — 1,989 — The Company entered into contingent consideration arrangements as a result of four acquisitions of real estate (see Note 3, “Real Estate Properties Held for Investment”). In order to determine the fair value of the Company’s contingent consideration arrangements, the Company used significant inputs not observable in the market to estimate the contingent consideration. In addition to using an appropriate discount rate, the Company used projections provided by the facilities to estimate future earnings at the facilities, then developed probability-weighted scenarios of the potential future performance of the tenant and the resulting payout from these scenarios. As of each of March 31, 2016 and December 31, 2015, the total contingent consideration liability was valued at $2.7 million and the contingent consideration asset was valued at $0.4 million .

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
EQUITY	EQUITY Preferred Stock On March 21, 2013, the Company completed an underwritten public offering of 5.8 million shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred Stock") at a price of $25.00 per share, pursuant to an effective registration statement. The Company received net proceeds of $138.3 million from the offering, after deducting underwriting discounts and other offering expenses. The Company classified the par value as preferred equity on its condensed consolidated balance sheets with the balance of the liquidation preference, net of any issuance costs, recorded as an increase in paid-in capital. The holders of the Company’s Series A Preferred Stock rank senior to the Company’s common stock with respect to dividend rights and rights upon the Company’s liquidation, dissolution or winding up of its affairs. At March 31, 2016 , there were no dividends in arrears. The Series A Preferred Stock does not have a stated maturity date, but the Company may redeem the Series A Preferred Stock on or after March 21, 2018, for $25.00 per share, plus any accrued and unpaid dividends. The Company may redeem the Series A Preferred Stock prior to March 21, 2018, in limited circumstances to preserve its status as a REIT or pursuant to a specified change of control. Upon the occurrence of a specified change of control, each holder of Series A Preferred Stock will have the right to convert some or all of the shares of Series A Preferred Stock held by such holder into a number of shares of the Company’s common stock equivalent to $25.00 plus accrued and unpaid dividends, but not to exceed a cap of 1.7864 shares of common stock per share of Series A Preferred Stock (subject to certain adjustments). Common Stock The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2016 : Declaration Date Record Date Amount Per Share Dividend Payable Date February 3, 2016 February 16, 2016 $ 0.41 February 29, 2016 During the three months ended March 31, 2016 , the Company issued 0.1 million shares of common stock as a result of restricted stock unit vestings and in connection with amounts payable under the Company's 2015 Bonus Plan pursuant to an election by certain participants to receive their bonus in the form of an equity award. Upon any payment of shares as a result of restricted stock unit vestings, the participant is required to satisfy the related tax withholding obligation. The 2009 Performance Incentive Plan provides that the Company has the right at its option to (a) require the participant to pay such tax withholding or (b) reduce the number of shares to be delivered by a number of shares necessary to satisfy the related minimum applicable statutory tax withholding obligation. During the three months ended March 31, 2016 , pursuant to advance elections made by certain participants, the Company incurred $1.1 million in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants. Accumulated Other Comprehensive Loss The following is a summary of the Company’s accumulated other comprehensive loss (in thousands): March 31, 2016 December 31, 2015 Foreign currency translation $ (2,006 ) $ (1,433 ) Unrealized losses on cash flow hedges (7,392 ) (5,900 ) Total accumulated other comprehensive loss $ (9,398 ) $ (7,333 )

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015 (in thousands, except share and per share amounts): Three Months Ended March 31, 2016 2015 Numerator Net (loss) income attributable to common stockholders $ (18,272 ) $ 16,889 Denominator Basic weighted average common shares and common equivalents 65,248,203 59,185,225 Dilutive restricted stock units — 374,028 Diluted weighted average common shares 65,248,203 59,559,253 Net (loss) income attributable to common stockholders, per: Basic common share $ (0.28 ) $ 0.29 Diluted common share $ (0.28 ) $ 0.28 Certain restricted stock units are considered participating securities because dividend payments are not forfeited even if the underlying award does not vest. Accordingly, the Company uses the two-class method when computing basic and diluted earnings per share. During the three months ended March 31, 2016 and 2015, approximately 54,000 and 300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.

SUMMARIZED CONDENSED CONSOLIDAT

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION	3 Months Ended
	Mar. 31, 2016
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION [Abstract]
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION	SUMMARIZED CONDENSED CONSOLIDATING INFORMATION In connection with the offerings of the Senior Notes by the Issuers, the Company and certain 100% owned subsidiaries of the Company (the “Guarantors”) have, jointly and severally, fully and unconditionally guaranteed the Senior Notes, subject to release under certain customary circumstances as described below. These guarantees are subordinated to all existing and future senior debt and senior guarantees of the Guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries. A Guarantor will be automatically and unconditionally released from its obligations under the guarantees with respect to the Senior Notes in the event of: • Any sale of the subsidiary Guarantor or of all or substantially all of its assets; • A merger or consolidation of a subsidiary Guarantor with an issuer of the Senior Notes or another Guarantor, provided that the surviving entity remains a Guarantor; • A subsidiary Guarantor is declared “unrestricted” for covenant purposes under the Senior Notes Indentures; • The requirements for legal defeasance or covenant defeasance or to discharge the Senior Notes Indentures have been satisfied; • A liquidation or dissolution, to the extent permitted under the Senior Notes Indentures, of a subsidiary Guarantor; and • The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty. Pursuant to Rule 3-10 of Regulation S-X, the following summarized condensed consolidating information is provided for the Company (the “Parent Company”), the Issuers, the Guarantors, and the Company’s non-Guarantor subsidiaries with respect to the Senior Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Issuers, the Guarantors and the non-Guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Issuers, the Guarantors or non-Guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra's proportionate share of each subsidiary's net assets. The Guarantor subsidiaries’ investments in the non-Guarantor subsidiaries and non-Guarantor subsidiaries’ investments in Guarantor subsidiaries are presented under the equity method of accounting. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the condensed consolidating statement of cash flows. Condensed consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Issuers, the combined Guarantor subsidiaries and the combined non-Guarantor subsidiaries, are as follows: CONDENSED CONSOLIDATING BALANCE SHEET March 31, 2016 (in thousands) (unaudited) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non- Guarantor Subsidiaries Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 119 $ — $ 1,701,093 $ 222,561 $ — $ 1,923,773 Loans receivable and other investments, net — — 299,675 — (2,167 ) 297,508 Cash and cash equivalents 3,789 — 1,726 3,618 — 9,133 Restricted cash — — 128 8,645 — 8,773 Assets held for sale — — 75,450 — — 75,450 Prepaid expenses, deferred financing costs and other assets, net 2,568 12,940 96,733 10,549 (3,271 ) 119,519 Intercompany 449,851 890,493 — — (1,340,344 ) — Investment in subsidiaries 561,125 796,160 56,849 — (1,414,134 ) — Total assets $ 1,017,452 $ 1,699,593 $ 2,231,654 $ 245,373 $ (2,759,916 ) $ 2,434,156 Liabilities Mortgage notes, net $ — $ — $ — $ 175,045 $ — $ 175,045 Revolving credit facility — 198,000 — — — 198,000 Term loans, net — 243,372 95,257 — — 338,629 Senior unsecured notes, net — 686,336 — — — 686,336 Liabilities held for sale — — 340 — — 340 Accounts payable and accrued liabilities 10,028 10,760 8,597 1,194 (2,271 ) 28,308 Intercompany — — 1,323,532 16,812 (1,340,344 ) — Total liabilities 10,028 1,138,468 1,427,726 193,051 (1,342,615 ) 1,426,658 Total Sabra Health Care REIT, Inc. stockholders' equity 1,007,424 561,125 803,928 52,248 (1,417,301 ) 1,007,424 Noncontrolling interests — — — 74 — 74 Total equity 1,007,424 561,125 803,928 52,322 (1,417,301 ) 1,007,498 Total liabilities and equity $ 1,017,452 $ 1,699,593 $ 2,231,654 $ 245,373 $ (2,759,916 ) $ 2,434,156 CONDENSED CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non- Guarantor Subsidiaries Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 48 $ — $ 1,816,813 $ 222,755 $ — $ 2,039,616 Loans receivable and other investments, net — — 302,282 — (2,105 ) 300,177 Cash and cash equivalents 2,548 — 1,008 3,878 — 7,434 Restricted cash — — 1,618 8,195 — 9,813 Prepaid expenses, deferred financing costs and other assets, net 2,047 13,384 89,590 9,522 (2,746 ) 111,797 Intercompany 489,763 918,209 — — (1,407,972 ) — Investment in subsidiaries 568,841 792,065 55,439 — (1,416,345 ) — Total assets $ 1,063,247 $ 1,723,658 $ 2,266,750 $ 244,350 $ (2,829,168 ) $ 2,468,837 Liabilities Mortgage notes, net $ — $ — $ — $ 174,846 $ — $ 174,846 Revolving credit facility — 255,000 — — — 255,000 Term loans, net — 200,000 64,229 — — 264,229 Senior unsecured notes, net — 685,704 — — — 685,704 Accounts payable and accrued liabilities 9,477 14,113 11,254 2,084 (1,746 ) 35,182 Intercompany — — 1,391,115 16,857 (1,407,972 ) — Total liabilities 9,477 1,154,817 1,466,598 193,787 (1,409,718 ) 1,414,961 Total Sabra Health Care REIT, Inc. stockholders' equity 1,053,770 568,841 800,152 50,457 (1,419,450 ) 1,053,770 Noncontrolling interests — — — 106 — 106 Total equity 1,053,770 568,841 800,152 50,563 (1,419,450 ) 1,053,876 Total liabilities and equity $ 1,063,247 $ 1,723,658 $ 2,266,750 $ 244,350 $ (2,829,168 ) $ 2,468,837 CONDENSED CONSOLIDATING STATEMENT OF LOSS For the Three Months Ended March 31, 2016 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non-Guarantor Elimination Consolidated Revenues: Rental income $ — $ — $ 48,858 $ 6,690 $ (236 ) $ 55,312 Interest and other income — 119 5,410 (15 ) (182 ) 5,332 Resident fees and services — — 1,344 571 — 1,915 Total revenues — 119 55,612 7,246 (418 ) 62,559 Expenses: Depreciation and amortization 183 — 15,509 2,074 — 17,766 Interest — 14,302 869 1,866 (119 ) 16,918 Operating expenses — — 967 681 (236 ) 1,412 General and administrative 4,473 10 169 62 — 4,714 Provision for doubtful accounts and loan losses 233 — 2,290 — — 2,523 Impairment of real estate — — 29,811 — — 29,811 Total expenses 4,889 14,312 49,615 4,683 (355 ) 73,144 Other income (expense): Loss on extinguishment of debt — (468 ) (88 ) — — (556 ) Other income (loss) — 500 (450 ) (50 ) — — Net loss on sales of real estate — — (4,602 ) — — (4,602 ) Total other income (expense) — 32 (5,140 ) (50 ) — (5,158 ) Income in subsidiary (10,759 ) 3,402 — — 7,357 — Net (loss) income (15,648 ) (10,759 ) 857 2,513 7,294 (15,743 ) Net loss attributable to noncontrolling interests — — — 32 — 32 Net (loss) income attributable to Sabra Health Care REIT, Inc. (15,648 ) (10,759 ) 857 2,545 7,294 (15,711 ) Preferred stock dividends (2,561 ) — — — — (2,561 ) Net (loss) income attributable to common stockholders $ (18,209 ) $ (10,759 ) $ 857 $ 2,545 $ 7,294 $ (18,272 ) Net loss attributable to common stockholders, per: Basic common share $ (0.28 ) Diluted common share $ (0.28 ) Weighted-average number of common shares outstanding, basic 65,248,203 Weighted-average number of common shares outstanding, diluted 65,248,203 CONDENSED CONSOLIDATING STATEMENT OF INCOME For the Three Months Ended March 31, 2015 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Revenues: Rental income $ — $ — $ 44,601 $ 4,904 $ — $ 49,505 Interest and other income 1 — 5,384 — — 5,385 Resident fees and services — — — 682 — 682 Total revenues 1 — 49,985 5,586 — 55,572 Expenses: Depreciation and amortization 13 — 12,702 1,435 — 14,150 Interest — 12,550 — 1,330 — 13,880 Operating expenses — — — 498 — 498 General and administrative 5,902 — 415 44 — 6,361 Provision for doubtful accounts (464 ) — 1,608 — — 1,144 Total expenses 5,451 12,550 14,725 3,307 — 36,033 Other income (expense): Other (expense) income — — (100 ) — — (100 ) Total other income (expense) — — (100 ) — — (100 ) Income in subsidiary 24,900 37,450 1,395 — (63,745 ) — Net income 19,450 24,900 36,555 2,279 (63,745 ) 19,439 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Sabra Health Care REIT, Inc. 19,450 24,900 36,555 2,290 (63,745 ) 19,450 Preferred dividends (2,561 ) — — — — (2,561 ) Net income attributable to common stockholders $ 16,889 $ 24,900 $ 36,555 $ 2,290 $ (63,745 ) $ 16,889 Net loss attributable to common stockholders, per: Basic common share $ 0.29 Diluted common share $ 0.28 Weighted-average number of common shares outstanding, basic 59,185,225 Weighted-average number of common shares outstanding, diluted 59,559,253 CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended March 31, 2016 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Net (loss) income $ (15,648 ) $ (10,759 ) $ 857 $ 2,513 $ 7,294 $ (15,743 ) Other comprehensive (loss) income: Foreign currency translation — (2,643 ) 1,632 438 — (573 ) Unrealized loss on cash flow hedge — (1,492 ) — — — (1,492 ) Total other comprehensive (loss) income — (4,135 ) 1,632 438 — (2,065 ) Comprehensive (loss) income (15,648 ) (14,894 ) 2,489 2,951 7,294 (17,808 ) Comprehensive loss attributable to noncontrolling interest — — — 32 — 32 Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc. $ (15,648 ) $ (14,894 ) $ 2,489 $ 2,983 $ 7,294 $ (17,776 ) CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the Three Months Ended March 31, 2015 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Net income 19,450 24,900 36,555 2,279 (63,745 ) 19,439 Other comprehensive loss: Unrealized loss on cash flow hedge — (1,545 ) — — — (1,545 ) Total other comprehensive loss — (1,545 ) — — — (1,545 ) Comprehensive income 19,450 23,355 36,555 2,279 (63,745 ) 17,894 Comprehensive loss attributable to noncontrolling interest — — — 11 — 11 Comprehensive income attributable to Sabra Health Care REIT, Inc. $ 19,450 $ 23,355 $ 36,555 $ 2,290 $ (63,745 ) $ 17,905 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (in thousands) (unaudited) Parent Company Issuers Combined Combined Non- Elimination Consolidated Net cash provided by operating activities $ 21,718 $ — $ 439 $ 2,569 $ — $ 24,726 Cash flows from investing activities: Origination and fundings of loans receivable — — (5,850 ) — — (5,850 ) Origination and fundings of preferred equity investments — — (984 ) — — (984 ) Additions to real estate (74 ) — (400 ) — — (474 ) Repayment of loans receivable — — 8,874 — — 8,874 Investment in subsidiary (200 ) (200 ) — — 400 — Net proceeds from the sale of real estate — — 398 — — 398 Distribution from subsidiary 2,025 2,025 — — (4,050 ) — Intercompany financing 8,347 25,621 — — (33,968 ) — Net cash provided by investing activities 10,098 27,446 2,038 — (37,618 ) 1,964 Cash flows from financing activities: Net repayments from revolving credit facility — (57,000 ) — — — (57,000 ) Proceeds from term loan — 45,000 24,360 — — 69,360 Principal payments on mortgage notes — — — (1,022 ) — (1,022 ) Payments of deferred financing costs — (5,274 ) (611 ) — — (5,885 ) Issuance of common stock (1,274 ) — — — — (1,274 ) Dividends paid on common and preferred stock (29,301 ) — — — — (29,301 ) Contribution from parent — 200 — 200 (400 ) — Distribution to parent — (2,025 ) — (2,025 ) 4,050 — Intercompany financing — (8,347 ) (25,621 ) — 33,968 — Net cash used by financing activities (30,575 ) (27,446 ) (1,872 ) (2,847 ) 37,618 (25,122 ) Net increase (decrease) in cash and cash equivalents 1,241 — 605 (278 ) — 1,568 Effect of foreign currency translation on cash and cash equivalents — — 113 18 — 131 Cash and cash equivalents, beginning of period 2,548 — 1,008 3,878 — 7,434 Cash and cash equivalents, end of period $ 3,789 $ — $ 1,726 $ 3,618 $ — $ 9,133 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2015 (in thousands) (unaudited) Parent Company Issuers Combined Combined Non- Elimination Consolidated Net cash provided by operating activities $ 23,502 $ — $ — $ 1,199 $ — $ 24,701 Cash flows from investing activities: Origination and fundings of loans receivable — — (7,303 ) — — (7,303 ) Origination and funding of preferred equity investments — — (311 ) — — (311 ) Additions to real estate (3 ) — (501 ) (171 ) — (675 ) Repayment of note receivable — — 2,052 — — 2,052 Investment in subsidiaries (414 ) (414 ) — 828 — Distribution from subsidiaries 1,355 1,355 — — (2,710 ) — Intercompany financing (48,175 ) (6,063 ) — — 54,238 — Net cash used in investing activities (47,237 ) (5,122 ) (6,063 ) (171 ) 52,356 (6,237 ) Cash flows from financing activities: Net repayments from prior revolving credit facility — (42,000 ) — — — (42,000 ) Principal payments on mortgage notes — — — (697 ) — (697 ) Payments of deferred financing costs — (112 ) — (18 ) — (130 ) Issuance of common stock (7,587 ) — — — — (7,587 ) Dividends paid (25,672 ) — — — — (25,672 ) Contribution from parent — 414 — 414 (828 ) — Distribution to parent — (1,355 ) — (1,355 ) 2,710 — Intercompany financing — 48,175 6,063 — (54,238 ) — Net cash (used in) provided by financing activities (33,259 ) 5,122 6,063 (1,656 ) (52,356 ) (76,086 ) Net decrease in cash and cash equivalents (56,994 ) — — (628 ) — (57,622 ) Cash and cash equivalents, beginning of period 58,799 — — 2,994 — 61,793 Cash and cash equivalents, end of period $ 1,805 $ — $ — $ 2,366 $ — $ 4,171

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Environmental As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of March 31, 2016 , the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations. Income Taxes As a result of the Company’s separation from Sun effective November 15, 2010 (the “Separation Date”), the Company is the surviving taxpayer for income tax purposes. Accordingly, tax positions taken prior to the Separation Date remained the Company’s obligations after the Separation Date. Sun agreed to indemnify the Company against, among other things, federal, state and local taxes (including penalties and interest) related to periods prior to the Separation Date to the extent the deferred tax assets allocated to the Company are not sufficient and/or cannot be utilized to satisfy these taxes. Effective December 1, 2012, Sun was acquired by Genesis HealthCare LLC. As a result of its acquisition of Sun, Genesis HealthCare LLC became successor to the obligations of Sun described above. Effective February 2, 2015, Genesis HealthCare LLC combined with Skilled Healthcare Group, Inc. and now operates under the name Genesis Healthcare, Inc. Legal Matters From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company's results of operations, financial condition or cash flows.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued. Dividend Declaration On May 2, 2016 , the Company announced that its board of directors declared a quarterly cash dividend of $0.42 per share of common stock. The dividend will be paid on May 31, 2016 to common stockholders of record as of the close of business on May 16, 2016 . On May 2, 2016 , the Company also announced that its board of directors declared a quarterly cash dividend of $0.4453125 per share of Series A Preferred Stock. The dividend will be paid on May 31, 2016 to preferred stockholders of record as of the close of business on May 16, 2016 . Sale of Forest Park - Frisco On April 1, 2016, the Company, along with the Forest Park Medical Center at Frisco, LLC (“Frisco Operator”) completed the sale of the Forest Park Medical Center - Frisco hospital (“Frisco Hospital”) to Columbia Medical Center of Plano Subsidiary, L.P., a subsidiary of HCA Holdings, Inc. for a total cash purchase price of $96.3 million , less the assumption of certain capital lease obligations of approximately $7.3 million . The Company received net cash proceeds of $86.6 million and expects to receive an additional $3.5 million from the collection of outstanding accounts receivable and cash held by the Frisco Hospital. Accordingly, during the three months ended March 31, 2016, the Company recognized a $29.8 million impairment charge on its investment in the Frisco Hospital and increased its loan loss reserve by $3.1 million based on what it expects to collect in connection with the Frisco Operator's debtor-in-possession loan from Sabra. These amounts are before consideration of the approximately $21.3 million in guarantees from the owners of the Frisco Operator.

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting	The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2016 and December 31, 2015 and for the periods ended March 31, 2016 and 2015. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 . For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s 2015 Annual Report on Form 10-K filed with the SEC.
Variable Interest Entities	GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity's activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity's activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity's activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity's equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity's economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2016 , the Company determined it was the primary beneficiary of two senior housing facilities and has consolidated the operations of the facilities in the accompanying condensed consolidated financial statements. As of March 31, 2016 , the Company determined that operations of the facilities were not material to the Company’s results of operations, financial condition or cash flows. As it relates to investments in loans, in addition to the Company's assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine if the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower's expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2016 , none of the Company's investments in loans are accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners' rights and their impact on the presumption of control of the limited partnership by any single partner. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners, the sole general partner increases or decreases its ownership of limited partnership interests, or there is an increase or decrease in the number of outstanding limited partnership interests. The Company also applies this guidance to managing member interests in limited liability companies.
Use of Estimates	The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Reclassifications	Certain amounts in the Company’s condensed consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated balance sheets and condensed consolidated statements of (loss) income.
Fair Value Disclosures	The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable : These instruments are presented in the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair value of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs. Preferred equity investments : These instruments are presented in the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair value of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs. Derivative instruments : The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate cap, interest rate swap and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which includes forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in level 2 of the fair value hierarchy. Senior Notes : These instruments are presented in the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums (discounts) and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2 inputs. Mortgage indebtedness : These instruments are presented in the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums (discounts) and not at fair value. The fair values of the Company’s mortgage notes payable were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3 inputs.
Recently Issued Accounting Standards Update	In January 2016, the FASB issued ASU 2016-01, Financial Instruments–Overall (Subtopic 825-10) (“ASU 2016-01”). ASU 2016-01 updates guidance related to recognition and measurement of financial assets and financial liabilities. ASU 2016-01 requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in ASU 2016-01 also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in ASU 2016-01 eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. ASU 2016-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting, however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In March 2016, the FASB issued ASU 2016-07, Equity Method and Joint Ventures (Topic 323) (“ASU 2016-07”). ASU 2016-07 simplifies the accounting for equity method investments. ASU 2016-07 eliminates the requirement in Topic 323 that an entity retroactively adopt the equity method of accounting if an investment qualifies for use of the equity method as a result of an increase in the level of ownership or degree of influence. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. ASU 2016-07 is effective for fiscal years and interim periods within those years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the amendments in ASU 2016-09 eliminate the guidance in Topic 718 that was indefinitely deferred shortly after the issuance of FASB Statement No. 123 (revised 2004), Share-Based Payment. ASU 2016-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

REAL ESTATE PROPERTIES HELD F23

REAL ESTATE PROPERTIES HELD FOR INVESTMENT (Tables)	3 Months Ended
	Mar. 31, 2016
Real Estate Investments, Net [Abstract]
Schedule of Real Estate Properties Held for Investment	The Company’s real estate properties held for investment (excluding properties classified as held for sale as of March 31, 2016 ) consisted of the following (dollars in thousands): As of March 31, 2016 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 102 11,535 $ 1,043,771 $ (180,184 ) $ 863,587 Senior Housing 75 6,727 1,060,635 (53,205 ) 1,007,430 Acute Care Hospital 1 70 61,640 (9,002 ) 52,638 178 18,332 2,166,046 (242,391 ) 1,923,655 Corporate Level 357 (239 ) 118 $ 2,166,403 $ (242,630 ) $ 1,923,773 As of December 31, 2015 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 103 11,515 $ 1,051,189 $ (174,662 ) $ 876,527 Senior Housing 75 6,710 1,050,162 (45,800 ) 1,004,362 Acute Care Hospitals 2 124 175,807 (17,127 ) 158,680 180 18,349 2,277,158 (237,589 ) 2,039,569 Corporate Level 299 (252 ) 47 $ 2,277,457 $ (237,841 ) $ 2,039,616 March 31, 2016 December 31, 2015 Building and improvements $ 1,863,888 $ 1,954,129 Furniture and equipment 82,110 97,840 Land improvements 3,811 3,594 Land 216,594 221,894 2,166,403 2,277,457 Accumulated depreciation (242,630 ) (237,841 ) $ 1,923,773 $ 2,039,616
Schedule of Future Minimum Rental Payments Receivable for Operating Leases	As of March 31, 2016 , the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases was as follows (in thousands): April 1, 2016 through December 31, 2016 $ 187,182 2017 207,388 2018 212,874 2019 219,026 2020 225,025 Thereafter 1,165,259 $ 2,216,754

LOANS RECEIVABLE AND OTHER IN24

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Loans Receivable and Other Investments [Abstract]
Schedule of Loans Receivable and Other Investments	As of March 31, 2016 and December 31, 2015 , the Company’s loans receivable and other investments consisted of the following (dollars in thousands): Investment Quantity Facility Type Principal Balance / Amount Funded as of March 31, 2016 Book Value as of March 31, 2016 Book Value as of Weighted Average Contractual Interest Rate / Rate of Return Weighted Average Annualized Effective Interest Rate / Rate of Return Maturity Dates Loans Receivable: Mortgage 8 Skilled Nursing / Senior Housing / Acute Care Hospital $ 166,610 $ 166,795 $ 166,277 8.4 % 8.2 % 6/30/16- 4/30/18 Construction 4 Acute Care Hospital / Senior Housing 75,380 75,526 75,201 14.0 % 13.9 % 9/30/16 - 3/31/21 Mezzanine 1 Skilled Nursing / Senior Housing 9,640 9,672 15,613 11.0 % 10.8 % 08/31/17 Pre-development 3 Senior Housing 3,767 3,839 3,768 9.0 % 7.7 % 1/28/17 - 9/09/17 Debtor-in-possession 1 Acute Care Hospital 16,418 16,418 13,625 5.0 % 5.0 % NA 17 271,815 272,250 274,484 9.8 % 9.7 % Loan loss reserve — (6,700 ) (4,300 ) $ 271,815 $ 265,550 $ 270,184 Other Investments: Preferred Equity 10 Skilled Nursing / Senior Housing 31,608 31,958 29,993 13.1 % 13.1 % N/A Total 27 $ 303,423 $ 297,508 $ 300,177 10.1 % 10.1 %

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Instrument [Line Items]
Schedule of Maturities of Debt	The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2016 (in thousands): Mortgage Indebtedness Revolving Credit Facility (1) Term Loans Senior Notes Total April 1, 2016 through December 31, 2016 $ 3,139 $ — $ — $ — $ 3,139 2017 4,310 — — — 4,310 2018 4,458 — — — 4,458 2019 4,612 — — — 4,612 2020 4,770 198,000 — — 202,770 Thereafter 156,728 — 341,387 700,000 1,198,115 Total Principal Balance 178,017 198,000 341,387 700,000 1,417,404 Discount — — — (598 ) (598 ) Deferred financing costs (2,972 ) — (2,758 ) (13,066 ) (18,796 ) Total Debt, net $ 175,045 $ 198,000 $ 338,629 $ 686,336 $ 1,398,010 (1) Revolving Credit Facility is subject to two six-month extension options.
Mortgages [Member]
Debt Instrument [Line Items]
Schedule of Long Term Debt	The Company’s mortgage notes payable consist of the following (dollars in thousands): Interest Rate Type Principal Balance as of (1) Principal Balance as of (1) Weighted Average (2) Maturity Date Fixed Rate $ 178,017 $ 177,850 4.01 % December 2021 - (1) Principal balance does not include deferred financing costs of $ 3.0 million as of March 31, 2016 and December 31, 2015. (2) Weighted average effective rate includes private mortgage insurance.
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Schedule of Long Term Debt	The Company’s senior unsecured notes consist of the following (dollars in thousands): Principal Balance as of Title Maturity Date March 31, 2016 (1) December 31, 2015 (1) 5.5% senior unsecured notes due 2021 (“2021 Notes”) February 1, 2021 $ 500,000 $ 500,000 5.375% senior unsecured notes due 2023 (“2023 Notes”) June 1, 2023 200,000 200,000 $ 700,000 $ 700,000 (1) Principal balance does not include discount of $ 0.6 million as of March 31, 2016 and December 31, 2015 and also excludes deferred financing costs of $13.1 million and $13.7 million as of

DERIVATIVE AND HEDGING INSTRU26

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Derivative and Financial Instruments Designated as Hedging Instruments	The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Maturity Dates Type Designation Count Fair Value Balance Sheet Location Assets: Interest rate cap Cash Flow 1 $ 670 $ 1,695 2019 Prepaid expenses, deferred financing costs and other assets, net Cross currency interest rate swaps Net Investment 2 2,838 5,392 2025 Prepaid expenses, deferred financing costs and other assets, net $ 3,508 $ 7,087 Liabilities: Interest rate swap Cash Flow 1 $ 1,989 $ 1,468 2020 Accounts payable and accrued liabilities CAD Term Loan Net Investment 1 96,388 64,890 2020 Term loans, net $ 98,377 $ 66,358
Schedule of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity	The following presents the effect of the Company’s derivative financial instruments on the condensed consolidated statements of (loss) income and the condensed consolidated statements of equity for the three months ended March 31, 2016 : Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion) Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion) Income Statement Location Three Months Ended March 31, 2016 2015 2016 2015 Cash Flow Hedges: Interest Rate Products $ (1,540 ) $ (1,545 ) $ (173 ) $ — Interest Expense Net Investment Hedges: Foreign Currency Products (2,503 ) — — — N/A CAD Term Loan 7,138 — — — N/A $ 3,095 $ (1,545 ) $ (173 ) $ —
Schedule of the Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Assets	The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2016 and December 31, 2015: As of March 31, 2016 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 3,508 $ — $ 3,508 $ (1,430 ) $ — $ 2,078 Offsetting Liabilities: Derivatives $ 1,989 $ — $ 1,989 $ (1,430 ) $ — $ 559 As of December 31, 2015 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 7,087 $ — $ 7,087 $ (1,468 ) $ — $ 5,619 Offsetting Liabilities: Derivatives $ 1,468 $ — $ 1,468 $ (1,468 ) $ — $ —
Schedule of the Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Liabilities	The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2016 and December 31, 2015: As of March 31, 2016 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 3,508 $ — $ 3,508 $ (1,430 ) $ — $ 2,078 Offsetting Liabilities: Derivatives $ 1,989 $ — $ 1,989 $ (1,430 ) $ — $ 559 As of December 31, 2015 Gross Amounts Not Offset in the Balance Sheet Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 7,087 $ — $ 7,087 $ (1,468 ) $ — $ 5,619 Offsetting Liabilities: Derivatives $ 1,468 $ — $ 1,468 $ (1,468 ) $ — $ —

FAIR VALUE DISCLOSURES (Tables)

FAIR VALUE DISCLOSURES (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Face Values, Carrying Amounts and Fair Values of Financial Instruments	The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2016 and December 31, 2015 whose carrying amounts do not approximate their fair value (in thousands): March 31, 2016 December 31, 2015 Carrying Amount (1) Face (2) Fair Value Carrying (1) Face (2) Fair Value Financial assets: Loans receivable $ 272,250 $ 271,815 $ 279,112 $ 270,184 $ 273,811 $ 274,628 Preferred equity investments 31,958 31,608 33,719 29,993 29,643 30,838 Financial liabilities: Senior Notes 686,336 700,000 697,250 685,704 700,000 718,500 Mortgage indebtedness 175,045 178,017 169,579 174,846 177,850 165,296 (1) Carrying amounts represent the book value of financial instruments and are net of unamortized premiums (discounts) and deferred financing costs. (2) Face value represents amounts contractually due under the terms of the respective agreements.
Schedule of Amounts Measured at Fair Value	During the three months ended March 31, 2016 , the Company recorded the following amounts measured at fair value (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Recurring Basis: Financial assets: Interest rate cap $ 670 $ — $ 670 $ — Cross currency swap 2,838 — 2,838 — Contingent consideration asset 350 — — 350 Financial liabilities: Contingent consideration liability 2,700 — — 2,700 Interest rate swap 1,989 — 1,989 —
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of Inputs used for Carrying Amounts which do not Approximate Fair Value with Valuation Methods	The Company determined the fair value of financial instruments as of March 31, 2016 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Financial assets: Loans receivable $ 279,112 $ — $ — $ 279,112 Preferred equity investments 33,719 — — 33,719 Financial liabilities: Senior Notes 697,250 — 697,250 — Mortgage indebtedness 169,579 — — 169,579

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Schedule of Cash Dividends on Common Stock Declared and Paid	The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2016 : Declaration Date Record Date Amount Per Share Dividend Payable Date February 3, 2016 February 16, 2016 $ 0.41 February 29, 2016
Summary of Accumulated Other Comprehensive Loss	The following is a summary of the Company’s accumulated other comprehensive loss (in thousands): March 31, 2016 December 31, 2015 Foreign currency translation $ (2,006 ) $ (1,433 ) Unrealized losses on cash flow hedges (7,392 ) (5,900 ) Total accumulated other comprehensive loss $ (9,398 ) $ (7,333 )

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of the Computation of Basic and Diluted Earnings Per Share	The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015 (in thousands, except share and per share amounts): Three Months Ended March 31, 2016 2015 Numerator Net (loss) income attributable to common stockholders $ (18,272 ) $ 16,889 Denominator Basic weighted average common shares and common equivalents 65,248,203 59,185,225 Dilutive restricted stock units — 374,028 Diluted weighted average common shares 65,248,203 59,559,253 Net (loss) income attributable to common stockholders, per: Basic common share $ (0.28 ) $ 0.29 Diluted common share $ (0.28 ) $ 0.28

SUMMARIZED CONDENSED CONSOLID30

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2016
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION [Abstract]
Schedule of Condensed Consolidating Balance Sheet (unaudited)	CONDENSED CONSOLIDATING BALANCE SHEET March 31, 2016 (in thousands) (unaudited) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non- Guarantor Subsidiaries Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 119 $ — $ 1,701,093 $ 222,561 $ — $ 1,923,773 Loans receivable and other investments, net — — 299,675 — (2,167 ) 297,508 Cash and cash equivalents 3,789 — 1,726 3,618 — 9,133 Restricted cash — — 128 8,645 — 8,773 Assets held for sale — — 75,450 — — 75,450 Prepaid expenses, deferred financing costs and other assets, net 2,568 12,940 96,733 10,549 (3,271 ) 119,519 Intercompany 449,851 890,493 — — (1,340,344 ) — Investment in subsidiaries 561,125 796,160 56,849 — (1,414,134 ) — Total assets $ 1,017,452 $ 1,699,593 $ 2,231,654 $ 245,373 $ (2,759,916 ) $ 2,434,156 Liabilities Mortgage notes, net $ — $ — $ — $ 175,045 $ — $ 175,045 Revolving credit facility — 198,000 — — — 198,000 Term loans, net — 243,372 95,257 — — 338,629 Senior unsecured notes, net — 686,336 — — — 686,336 Liabilities held for sale — — 340 — — 340 Accounts payable and accrued liabilities 10,028 10,760 8,597 1,194 (2,271 ) 28,308 Intercompany — — 1,323,532 16,812 (1,340,344 ) — Total liabilities 10,028 1,138,468 1,427,726 193,051 (1,342,615 ) 1,426,658 Total Sabra Health Care REIT, Inc. stockholders' equity 1,007,424 561,125 803,928 52,248 (1,417,301 ) 1,007,424 Noncontrolling interests — — — 74 — 74 Total equity 1,007,424 561,125 803,928 52,322 (1,417,301 ) 1,007,498 Total liabilities and equity $ 1,017,452 $ 1,699,593 $ 2,231,654 $ 245,373 $ (2,759,916 ) $ 2,434,156 CONDENSED CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non- Guarantor Subsidiaries Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 48 $ — $ 1,816,813 $ 222,755 $ — $ 2,039,616 Loans receivable and other investments, net — — 302,282 — (2,105 ) 300,177 Cash and cash equivalents 2,548 — 1,008 3,878 — 7,434 Restricted cash — — 1,618 8,195 — 9,813 Prepaid expenses, deferred financing costs and other assets, net 2,047 13,384 89,590 9,522 (2,746 ) 111,797 Intercompany 489,763 918,209 — — (1,407,972 ) — Investment in subsidiaries 568,841 792,065 55,439 — (1,416,345 ) — Total assets $ 1,063,247 $ 1,723,658 $ 2,266,750 $ 244,350 $ (2,829,168 ) $ 2,468,837 Liabilities Mortgage notes, net $ — $ — $ — $ 174,846 $ — $ 174,846 Revolving credit facility — 255,000 — — — 255,000 Term loans, net — 200,000 64,229 — — 264,229 Senior unsecured notes, net — 685,704 — — — 685,704 Accounts payable and accrued liabilities 9,477 14,113 11,254 2,084 (1,746 ) 35,182 Intercompany — — 1,391,115 16,857 (1,407,972 ) — Total liabilities 9,477 1,154,817 1,466,598 193,787 (1,409,718 ) 1,414,961 Total Sabra Health Care REIT, Inc. stockholders' equity 1,053,770 568,841 800,152 50,457 (1,419,450 ) 1,053,770 Noncontrolling interests — — — 106 — 106 Total equity 1,053,770 568,841 800,152 50,563 (1,419,450 ) 1,053,876 Total liabilities and equity $ 1,063,247 $ 1,723,658 $ 2,266,750 $ 244,350 $ (2,829,168 ) $ 2,468,837
Schedule of Condensed Consolidating Statement of Income (unaudited)	CONDENSED CONSOLIDATING STATEMENT OF LOSS For the Three Months Ended March 31, 2016 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Guarantor Subsidiaries Combined Non-Guarantor Elimination Consolidated Revenues: Rental income $ — $ — $ 48,858 $ 6,690 $ (236 ) $ 55,312 Interest and other income — 119 5,410 (15 ) (182 ) 5,332 Resident fees and services — — 1,344 571 — 1,915 Total revenues — 119 55,612 7,246 (418 ) 62,559 Expenses: Depreciation and amortization 183 — 15,509 2,074 — 17,766 Interest — 14,302 869 1,866 (119 ) 16,918 Operating expenses — — 967 681 (236 ) 1,412 General and administrative 4,473 10 169 62 — 4,714 Provision for doubtful accounts and loan losses 233 — 2,290 — — 2,523 Impairment of real estate — — 29,811 — — 29,811 Total expenses 4,889 14,312 49,615 4,683 (355 ) 73,144 Other income (expense): Loss on extinguishment of debt — (468 ) (88 ) — — (556 ) Other income (loss) — 500 (450 ) (50 ) — — Net loss on sales of real estate — — (4,602 ) — — (4,602 ) Total other income (expense) — 32 (5,140 ) (50 ) — (5,158 ) Income in subsidiary (10,759 ) 3,402 — — 7,357 — Net (loss) income (15,648 ) (10,759 ) 857 2,513 7,294 (15,743 ) Net loss attributable to noncontrolling interests — — — 32 — 32 Net (loss) income attributable to Sabra Health Care REIT, Inc. (15,648 ) (10,759 ) 857 2,545 7,294 (15,711 ) Preferred stock dividends (2,561 ) — — — — (2,561 ) Net (loss) income attributable to common stockholders $ (18,209 ) $ (10,759 ) $ 857 $ 2,545 $ 7,294 $ (18,272 ) Net loss attributable to common stockholders, per: Basic common share $ (0.28 ) Diluted common share $ (0.28 ) Weighted-average number of common shares outstanding, basic 65,248,203 Weighted-average number of common shares outstanding, diluted 65,248,203 CONDENSED CONSOLIDATING STATEMENT OF INCOME For the Three Months Ended March 31, 2015 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Revenues: Rental income $ — $ — $ 44,601 $ 4,904 $ — $ 49,505 Interest and other income 1 — 5,384 — — 5,385 Resident fees and services — — — 682 — 682 Total revenues 1 — 49,985 5,586 — 55,572 Expenses: Depreciation and amortization 13 — 12,702 1,435 — 14,150 Interest — 12,550 — 1,330 — 13,880 Operating expenses — — — 498 — 498 General and administrative 5,902 — 415 44 — 6,361 Provision for doubtful accounts (464 ) — 1,608 — — 1,144 Total expenses 5,451 12,550 14,725 3,307 — 36,033 Other income (expense): Other (expense) income — — (100 ) — — (100 ) Total other income (expense) — — (100 ) — — (100 ) Income in subsidiary 24,900 37,450 1,395 — (63,745 ) — Net income 19,450 24,900 36,555 2,279 (63,745 ) 19,439 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Sabra Health Care REIT, Inc. 19,450 24,900 36,555 2,290 (63,745 ) 19,450 Preferred dividends (2,561 ) — — — — (2,561 ) Net income attributable to common stockholders $ 16,889 $ 24,900 $ 36,555 $ 2,290 $ (63,745 ) $ 16,889 Net loss attributable to common stockholders, per: Basic common share $ 0.29 Diluted common share $ 0.28 Weighted-average number of common shares outstanding, basic 59,185,225 Weighted-average number of common shares outstanding, diluted 59,559,253
Schedule of Condensed Consolidating Statement of Comprehensive Income	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended March 31, 2016 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Net (loss) income $ (15,648 ) $ (10,759 ) $ 857 $ 2,513 $ 7,294 $ (15,743 ) Other comprehensive (loss) income: Foreign currency translation — (2,643 ) 1,632 438 — (573 ) Unrealized loss on cash flow hedge — (1,492 ) — — — (1,492 ) Total other comprehensive (loss) income — (4,135 ) 1,632 438 — (2,065 ) Comprehensive (loss) income (15,648 ) (14,894 ) 2,489 2,951 7,294 (17,808 ) Comprehensive loss attributable to noncontrolling interest — — — 32 — 32 Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc. $ (15,648 ) $ (14,894 ) $ 2,489 $ 2,983 $ 7,294 $ (17,776 ) CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the Three Months Ended March 31, 2015 (dollars in thousands, except per share amounts) (unaudited) Parent Company Issuers Combined Combined Non-Guarantor Elimination Consolidated Net income 19,450 24,900 36,555 2,279 (63,745 ) 19,439 Other comprehensive loss: Unrealized loss on cash flow hedge — (1,545 ) — — — (1,545 ) Total other comprehensive loss — (1,545 ) — — — (1,545 ) Comprehensive income 19,450 23,355 36,555 2,279 (63,745 ) 17,894 Comprehensive loss attributable to noncontrolling interest — — — 11 — 11 Comprehensive income attributable to Sabra Health Care REIT, Inc. $ 19,450 $ 23,355 $ 36,555 $ 2,290 $ (63,745 ) $ 17,905
Schedule of Condensed Consolidating Statement of Cash Flows (unaudited)	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (in thousands) (unaudited) Parent Company Issuers Combined Combined Non- Elimination Consolidated Net cash provided by operating activities $ 21,718 $ — $ 439 $ 2,569 $ — $ 24,726 Cash flows from investing activities: Origination and fundings of loans receivable — — (5,850 ) — — (5,850 ) Origination and fundings of preferred equity investments — — (984 ) — — (984 ) Additions to real estate (74 ) — (400 ) — — (474 ) Repayment of loans receivable — — 8,874 — — 8,874 Investment in subsidiary (200 ) (200 ) — — 400 — Net proceeds from the sale of real estate — — 398 — — 398 Distribution from subsidiary 2,025 2,025 — — (4,050 ) — Intercompany financing 8,347 25,621 — — (33,968 ) — Net cash provided by investing activities 10,098 27,446 2,038 — (37,618 ) 1,964 Cash flows from financing activities: Net repayments from revolving credit facility — (57,000 ) — — — (57,000 ) Proceeds from term loan — 45,000 24,360 — — 69,360 Principal payments on mortgage notes — — — (1,022 ) — (1,022 ) Payments of deferred financing costs — (5,274 ) (611 ) — — (5,885 ) Issuance of common stock (1,274 ) — — — — (1,274 ) Dividends paid on common and preferred stock (29,301 ) — — — — (29,301 ) Contribution from parent — 200 — 200 (400 ) — Distribution to parent — (2,025 ) — (2,025 ) 4,050 — Intercompany financing — (8,347 ) (25,621 ) — 33,968 — Net cash used by financing activities (30,575 ) (27,446 ) (1,872 ) (2,847 ) 37,618 (25,122 ) Net increase (decrease) in cash and cash equivalents 1,241 — 605 (278 ) — 1,568 Effect of foreign currency translation on cash and cash equivalents — — 113 18 — 131 Cash and cash equivalents, beginning of period 2,548 — 1,008 3,878 — 7,434 Cash and cash equivalents, end of period $ 3,789 $ — $ 1,726 $ 3,618 $ — $ 9,133 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2015 (in thousands) (unaudited) Parent Company Issuers Combined Combined Non- Elimination Consolidated Net cash provided by operating activities $ 23,502 $ — $ — $ 1,199 $ — $ 24,701 Cash flows from investing activities: Origination and fundings of loans receivable — — (7,303 ) — — (7,303 ) Origination and funding of preferred equity investments — — (311 ) — — (311 ) Additions to real estate (3 ) — (501 ) (171 ) — (675 ) Repayment of note receivable — — 2,052 — — 2,052 Investment in subsidiaries (414 ) (414 ) — 828 — Distribution from subsidiaries 1,355 1,355 — — (2,710 ) — Intercompany financing (48,175 ) (6,063 ) — — 54,238 — Net cash used in investing activities (47,237 ) (5,122 ) (6,063 ) (171 ) 52,356 (6,237 ) Cash flows from financing activities: Net repayments from prior revolving credit facility — (42,000 ) — — — (42,000 ) Principal payments on mortgage notes — — — (697 ) — (697 ) Payments of deferred financing costs — (112 ) — (18 ) — (130 ) Issuance of common stock (7,587 ) — — — — (7,587 ) Dividends paid (25,672 ) — — — — (25,672 ) Contribution from parent — 414 — 414 (828 ) — Distribution to parent — (1,355 ) — (1,355 ) 2,710 — Intercompany financing — 48,175 6,063 — (54,238 ) — Net cash (used in) provided by financing activities (33,259 ) 5,122 6,063 (1,656 ) (52,356 ) (76,086 ) Net decrease in cash and cash equivalents (56,994 ) — — (628 ) — (57,622 ) Cash and cash equivalents, beginning of period 58,799 — — 2,994 — 61,793 Cash and cash equivalents, end of period $ 1,805 $ — $ — $ 2,366 $ — $ 4,171

SUMMARY OF SIGNIFICANT ACCOUN31

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016variable_interest_entityInvestment	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Number of VIEs | variable_interest_entity	2
Number of investments in loans accounted for as real estate joint ventures | Investment	0
Prepaid expenses, deferred financing costs and other assets, net [Member]
Debt Instrument [Line Items]
Deferred financing costs		$ (17.3)
Long-term Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs		$ 17.3

REAL ESTATE PROPERTIES HELD F32

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Schedule of Real Estate Properties Held for Investment (Details) $ in Thousands	Mar. 31, 2016USD ($)BedFacilitiy	Dec. 31, 2015USD ($)BedFacilitiy
Real Estate Properties [Line Items]
Building and improvements	$ 1,863,888	$ 1,954,129
Furniture and equipment	82,110	97,840
Land improvements	3,811	3,594
Land	216,594	221,894
Total Real Estate at Cost	2,166,403	2,277,457
Accumulated Depreciation	(242,630)	(237,841)
Total Real Estate Investments, Net	$ 1,923,773	$ 2,039,616
Operating Segments [Member]
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	178	180
Number of Beds/Units | Bed	18,332	18,349
Total Real Estate at Cost	$ 2,166,046	$ 2,277,158
Accumulated Depreciation	(242,391)	(237,589)
Total Real Estate Investments, Net	$ 1,923,655	$ 2,039,569
Skilled Nursing/Transitional Care Facilities [Member]
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	102	103
Number of Beds/Units | Bed	11,535	11,515
Total Real Estate at Cost	$ 1,043,771	$ 1,051,189
Accumulated Depreciation	(180,184)	(174,662)
Total Real Estate Investments, Net	$ 863,587	$ 876,527
Senior Housing [Member]
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	75	75
Number of Beds/Units | Bed	6,727	6,710
Total Real Estate at Cost	$ 1,060,635	$ 1,050,162
Accumulated Depreciation	(53,205)	(45,800)
Total Real Estate Investments, Net	$ 1,007,430	$ 1,004,362
Acute Care Hospital [Member]
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	1	2
Number of Beds/Units | Bed	70	124
Total Real Estate at Cost	$ 61,640	$ 175,807
Accumulated Depreciation	(9,002)	(17,127)
Total Real Estate Investments, Net	52,638	158,680
Corporate [Member]
Real Estate Properties [Line Items]
Total Real Estate at Cost	357	299
Accumulated Depreciation	(239)	(252)
Total Real Estate Investments, Net	$ 118	$ 47

REAL ESTATE PROPERTIES HELD F33

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Narrative (Details)	3 Months Ended
	Mar. 31, 2016USD ($)acquisitionCustomer	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)
Real Estate Properties [Line Items]
Number of acquired properties | acquisition	4
Estimated earn-out value	$ 3,200,000
Change in fair value of contingent consideration	$ 0	$ (100,000)
Weighted average lease expiration period	10 years
Security deposit liability	$ 1,400,000		$ 1,300,000
Reserve for unpaid cash rents	3,500,000		3,500,000
Allowance for straight-line rental income	$ 5,500,000		$ 5,300,000
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Real Estate Properties [Line Items]
Number of major customers | Customer	3
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Genesis [Member]
Real Estate Properties [Line Items]
Concentration risk percent	33.90%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Holiday [Member]
Real Estate Properties [Line Items]
Concentration risk percent	16.70%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | NMS [Member]
Real Estate Properties [Line Items]
Concentration risk percent	10.40%
Minimum [Member]
Real Estate Properties [Line Items]
Lease expiration period	1 year
Maximum [Member]
Real Estate Properties [Line Items]
Lease expiration period	17 years
Accounts Payable and Accrued Liabilities [Member]
Real Estate Properties [Line Items]
Contingent consideration liability	$ 2,700,000
Prepaid expenses, deferred financing costs and other assets, net [Member]
Real Estate Properties [Line Items]
Contingent consideration asset	$ 300,000

REAL ESTATE PROPERTIES HELD F34

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Schedule of Future Minimum Rental Payments Receivable for Operating Leases (Details) $ in Thousands	Mar. 31, 2016USD ($)
Operating Leases, Future Minimum Payments Receivable [Abstract]
April 1, 2016 through December 31, 2016	$ 187,182
2,017	207,388
2,018	212,874
2,019	219,026
2,020	225,025
Thereafter	1,165,259
Total	$ 2,216,754

ASSETS HELD FOR SALE AND DISP35

ASSETS HELD FOR SALE AND DISPOSITIONS - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)Facilitiy	Mar. 31, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of real estate	$ 29,811	$ 0
Net (loss) income from facilities	$ (1,200)	$ 1,000
Acute Care Hospital [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate held-for-sale | Facilitiy	1
Net book value of investment	$ 75,100
Impairment of real estate	$ 29,800
Skilled Nursing Facilities [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties disposed of | Facilitiy	1
Consideration	$ 400
Selling expenses	100
Carrying value of the assets and liabilities	5,000
Loss from sale	$ (4,600)

LOANS RECEIVABLE AND OTHER IN36

LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Loans Receivable and Other Investments (Details) $ in Thousands	Mar. 31, 2016USD ($)loan	Dec. 31, 2015USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	17
Loans Receivable, Principal Balance	$ 271,815
Loans Receivable, Book Value	$ 272,250	$ 274,484
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	9.80%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	9.70%
Loan loss allowance	$ (6,700)	(4,300)
Loans Receivable, Net Amount	$ 265,550	270,184
Preferred Equity Investment, Quantity | loan	10
Preferred Equity Investment, Principal Balance	$ 31,608	29,643
Preferred Equity Investment, Book Value	$ 31,958	29,993
Preferred Equity Investment, Weighted Average Contractual Interest Rate / Rate of Return	13.10%
Preferred Equity Investment, Weighted Average Annualized Effective Interest Rate / Rate of Return	13.10%
Total Investments, Quantity | loan	27
Total Investments, Principal Balance	$ 303,423
Total Investments, Book Value	$ 297,508	300,177
Total Investments, Weighted Average Contractual Interest Rate / Rate of Return	10.10%
Total Investments, Weighted Average Annualized Effective Interest Rate / Rate of Return	10.10%
Mortgage [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	8
Loans Receivable, Principal Balance	$ 166,610
Loans Receivable, Book Value	$ 166,795	166,277
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	8.40%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	8.20%
Construction [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	4
Loans Receivable, Principal Balance	$ 75,380
Loans Receivable, Book Value	$ 75,526	75,201
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	14.00%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	13.90%
Mezzanine [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	1
Loans Receivable, Principal Balance	$ 9,640
Loans Receivable, Book Value	$ 9,672	15,613
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	11.00%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	10.80%
Pre-development [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	3
Loans Receivable, Principal Balance	$ 3,767
Loans Receivable, Book Value	$ 3,839	3,768
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	9.00%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	7.70%
Debtor-in-possession [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Quantity | loan	1
Loans Receivable, Principal Balance	$ 16,418
Loans Receivable, Book Value	$ 16,418	$ 13,625
Loans Receivable, Weighted Average Contractual Interest Rate / Rate of Return	5.00%
Loans Receivable, Weighted Average Annualized Effective Interest Rate / Rate of Return	5.00%

LOANS RECEIVABLE AND OTHER IN37

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)loan	Dec. 31, 2015USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loan receivable investments | loan	17
Principal balance	$ 271,815
Loan loss reserve	$ 6,700	$ 4,300
Loan Receivable Investment [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loan receivable investments | loan	2
Principal balance	$ 29,800
Loan loss reserve in period	2,300
Loan loss reserve	$ 4,800
Number of loan receivable investments, nonaccrual status | loan	2
Loans receivable, nonaccrual status	$ 123,500
Loan Receivable Investment [Member] | Over 90 days past due [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loan receivable investments | loan	1
Principal balance	$ 60,900
Portfolio-Based Loan Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan loss reserve in period	100
Loan loss reserve	$ 1,900

DEBT - Schedule of Long Term De

DEBT - Schedule of Long Term Debt - Mortgage Notes (Details) - Mortgages [Member] - Fixed Rate Mortgages [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Principal Balance	$ 178,017	$ 177,850
Weighted Average Effective Interest Rate	4.01%

DEBT - Schedule of Long Term 39

DEBT - Schedule of Long Term Debt - Mortgage Notes (Footnote) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Deferred financing costs	$ (18,796)
Mortgages [Member]
Debt Instrument [Line Items]
Deferred financing costs	(2,972)
Mortgages [Member] | Fixed Rate Mortgages [Member]
Debt Instrument [Line Items]
Deferred financing costs	$ (3,000)	$ (3,000)

DEBT - Narrative (Details)

DEBT - Narrative (Details)	Jan. 14, 2016USD ($)extension_optioninvestment_grading_company	Jun. 10, 2015USD ($)	Oct. 10, 2014USD ($)	Sep. 10, 2014USD ($)	Mar. 31, 2016USD ($)extension_option	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Jan. 14, 2016CADextension_optioninvestment_grading_company	Jun. 10, 2015CAD
Debt Instrument [Line Items]
Revolving credit facility					$ 198,000,000		$ 255,000,000
Interest expense					16,918,000	$ 13,880,000
Number of investment grading companies | investment_grading_company	2							2
Deferred financing costs amortization included in interest expense					1,221,000	$ 1,261,000
Accrued interest					$ 9,500,000		$ 13,300,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Number of optional extensions | extension_option					2
Optional extension period					6 months
5.5% Senior Unsecured Notes due 2021 [Member]
Debt Instrument [Line Items]
Interest rate					5.50%
5.375% Senior Unsecured Notes Due 2023 [Member]
Debt Instrument [Line Items]
Interest rate					5.375%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Borrowing capacity				$ 650,000,000
Accordion feature, additional capacity				$ 100,000,000
Term loan			$ 200,000,000
Interest rate cap contract term			5 years
Interest rate							3.03%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Annum percent unused borrowing fee							0.25%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Annum percent unused borrowing fee							0.35%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate			2.00%	1.00%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				2.00%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				2.60%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Federal Funds Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				0.50%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				1.00%
Prior Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				1.60%
Prior Canadian Term Loan [Member]
Debt Instrument [Line Items]
Interest rate swap, fixed		1.59%							1.59%
Prior Canadian Term Loan [Member] | Sabra Canadian Holdings, LLC [Member]
Debt Instrument [Line Items]
Debt amount		$ 73,200,000							CAD 90,000,000
Prior Canadian Term Loan [Member] | Canadian Dollar Offer Rate (CDOR) [Member] | Minimum [Member] | Sabra Canadian Holdings, LLC [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		2.00%
Prior Canadian Term Loan [Member] | Canadian Dollar Offer Rate (CDOR) [Member] | Maximum [Member] | Sabra Canadian Holdings, LLC [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		2.60%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Borrowing capacity	$ 500,000,000
Borrowing capacity in certain foreign currencies (up to)	$ 125,000,000
Number of optional extensions | extension_option	2							2
Optional extension period	6 months
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.25%
Facility fee, contingent event	0.125%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.30%
Facility fee, contingent event	0.30%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.80%
Basis spread on variable rate, contingent event	0.90%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.40%
Basis spread on variable rate, contingent event	1.70%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Federal Funds Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	0.80%
Basis spread on variable rate, contingent event	0.00%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.40%
Basis spread on variable rate, contingent event	0.70%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) Or Canadian Dollar Offer Rate (CDOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate, contingent event	1.00%
Current Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) Or Canadian Dollar Offer Rate (CDOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate, contingent event	1.95%
U.S. Dollar Term Loan [Member]
Debt Instrument [Line Items]
Debt amount	$ 245,000,000
U.S. Dollar Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
U.S. Dollar Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.35%
U.S. Dollar Term Loan [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	0.75%
U.S. Dollar Term Loan [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.35%
U.S. Dollar Term Loan [Member] | Canadian Dollar Offer Rate (CDOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
U.S. Dollar Term Loan [Member] | Canadian Dollar Offer Rate (CDOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.35%
U.S. Dollar Term Loan [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate, contingent event	0.00%
U.S. Dollar Term Loan [Member] | Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate, contingent event	0.95%
Canadian Term Loan [Member]
Debt Instrument [Line Items]
Debt amount | CAD								CAD 125,000,000
Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Accordion feature, additional capacity	$ 1,250,000,000
Revolving Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Interest rate					2.84%
Revolving credit facility					$ 198,000,000
Available borrowing capacity					302,000,000
Interest expense					1,500,000
Unused facility fees					$ 200,000

DEBT - Schedule of Long Term 41

DEBT - Schedule of Long Term Debt - Senior Unsecured Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Principal Balance	$ 700,000	$ 700,000
5.5% Senior Unsecured Notes due 2021 [Member]
Debt Instrument [Line Items]
Principal Balance	500,000	500,000
5.375% Senior Unsecured Notes Due 2023 [Member]
Debt Instrument [Line Items]
Principal Balance	$ 200,000	$ 200,000

DEBT - Schedule of Long Term 42

DEBT - Schedule of Long Term Debt - Senior Unsecured Notes (Footnote) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Instrument, Unamortized Discount	$ 598
Debt Instrument [Line Items]
Deferred financing costs	18,796
Senior Notes [Member]
Debt Disclosure [Abstract]
Debt Instrument, Unamortized Discount	598
Debt Instrument [Line Items]
Debt discount not included in outstanding principal balance		$ 600
Deferred financing costs	$ 13,066	$ 13,700

DEBT - Schedule of Maturities o

DEBT - Schedule of Maturities of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
April 1, 2016 through December 31, 2016	$ 3,139
2,017	4,310
2,018	4,458
2,019	4,612
2,020	202,770
Thereafter	1,198,115
Total Principal Balance	1,417,404
Discount	(598)
Deferred financing costs	(18,796)
Total Debt, net	1,398,010
Mortgage Indebtedness [Member]
Debt Instrument [Line Items]
April 1, 2016 through December 31, 2016	3,139
2,017	4,310
2,018	4,458
2,019	4,612
2,020	4,770
Thereafter	156,728
Total Principal Balance	178,017
Discount	0
Deferred financing costs	(2,972)
Total Debt, net	175,045
Senior Notes [Member]
Debt Instrument [Line Items]
April 1, 2016 through December 31, 2016	0
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	700,000
Total Principal Balance	700,000
Discount	(598)
Deferred financing costs	(13,066)	$ (13,700)
Total Debt, net	686,336
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
April 1, 2016 through December 31, 2016	0
2,017	0
2,018	0
2,019	0
2,020	198,000
Thereafter	0
Total Principal Balance	198,000
Discount	0
Deferred financing costs	0
Total Debt, net	198,000
Term Loans [Member]
Debt Instrument [Line Items]
April 1, 2016 through December 31, 2016	0
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	341,387
Total Principal Balance	341,387
Discount	0
Deferred financing costs	(2,758)
Total Debt, net	$ 338,629

DEBT - Schedule of Maturities44

DEBT - Schedule of Maturities of Debt (Footnote) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016extension_option	Dec. 31, 2015USD ($)
Senior Notes [Member]
Debt Instrument [Line Items]
Debt discount not included in outstanding principal balance | $		$ 0.6
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Number of optional extensions | extension_option	2
Optional extension period	6 months

DERIVATIVE AND HEDGING INSTRU45

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)	3 Months Ended
	Mar. 31, 2016USD ($)	Mar. 31, 2016CAD	Dec. 31, 2015USD ($)	Dec. 31, 2015CAD
Derivative [Line Items]
Financial liability	$ 1,989,000		$ 1,468,000
Fair value of derivatives in a net liability position	1,100,000
Termination value of derivatives in a net liability position	1,100,000
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Financial liability	98,377,000		66,358,000
Designated as Hedging Instrument [Member] | Cash Flow Hedges [Member] | Interest Rate Cap [Member]
Derivative [Line Items]
Notional amount	200,000,000		200,000,000
Losses included in accumulated other comprehensive loss which are expected to be reclassified into earnings in the next 12 months	1,300,000
Designated as Hedging Instrument [Member] | Cash Flow Hedges [Member] | Interest Rate Swap [Member]
Derivative [Line Items]
Notional amount	69,400,000	CAD 90,000,000	64,900,000	CAD 90,000,000
Designated as Hedging Instrument [Member] | Net Investment Hedges [Member]
Derivative [Line Items]
Financial liability	96,400,000	125,000,000
Designated as Hedging Instrument [Member] | Net Investment Hedges [Member] | Cross Currency Interest Rate Swaps [Member]
Derivative [Line Items]
Notional amount	$ 43,400,000	CAD 56,300,000	$ 40,600,000

DERIVATIVE AND HEDGING INSTRU46

DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands, CAD in Millions	Mar. 31, 2016USD ($)instrument	Mar. 31, 2016CADinstrument	Dec. 31, 2015USD ($)
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 3,508		$ 7,087
Derivative Liability	1,989		1,468
Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	3,508		7,087
Derivative Liability	98,377		66,358
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	$ 96,400	CAD 125
Designated as Hedging Instrument [Member] | Interest Rate Cap [Member] | Cash Flow Hedging [Member] | Prepaid expenses, deferred financing costs and other assets, net [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Count | instrument	1	1
Derivative Asset	$ 670		1,695
Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Swaps [Member] | Net Investment Hedging [Member] | Prepaid expenses, deferred financing costs and other assets, net [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Count | instrument	2	2
Derivative Asset	$ 2,838		5,392
Designated as Hedging Instrument [Member] | Interest Rate Swap [Member] | Cash Flow Hedging [Member] | Accounts Payable and Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Count | instrument	1	1
Derivative Liability	$ 1,989		1,468
Designated as Hedging Instrument [Member] | CAD Term Loan [Member] | Net Investment Hedging [Member] | Term Loan [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Count | instrument	1	1
Derivative Liability	$ 96,388		$ 64,890

DERIVATIVE AND HEDGING INSTRU47

DERIVATIVE AND HEDGING INSTRUMENTS - Schedule of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion)	$ 3,095	$ (1,545)
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion)	(173)	0
Interest Rate Products [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion)	(1,540)	(1,545)
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion)	(173)	0
Foreign Currency Products [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion)	(2,503)	0
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion)	0	0
CAD Term Loan [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion)	7,138	0
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (Effective Portion)	$ 0	$ 0

DERIVATIVE AND HEDGING INSTRU48

DERIVATIVE AND HEDGING INSTRUMENTS - Schedule of the Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Offsetting Assets, Gross Amounts of Recognized Assets / Liabilities	$ 3,508	$ 7,087
Offsetting Assets, Gross Amounts Offset in the Balance Sheet	0	0
Offsetting Assets, Net Amounts of Assets / Liabilities presented in the Balance Sheet	3,508	7,087
Offsetting Assets, Gross Amounts Not Offset in the Balance Sheet, Financial Instruments	(1,430)	(1,468)
Offsetting Assets, Gross Amounts Not Offset in the Balance Sheet, Cash Collateral Received	0	0
Offsetting Assets, Net Amount	2,078	5,619
Offsetting Liabilities, Gross Amounts of Recognized Assets / Liabilities	1,989	1,468
Offsetting Liabilities, Gross Amounts Offset in the Balance Sheet	0	0
Offsetting Liabilities, Net Amounts of Assets / Liabilities presented in the Balance Sheet	1,989	1,468
Offsetting Liabilities, Gross Amounts Not Offset in the Balance Sheet, Financial Instruments	(1,430)	(1,468)
Offsetting Liabilities, Gross Amounts Not Offset in the Balance Sheet, Cash Collateral Received	0	0
Offsetting Liabilities, Net Amount	$ 559	$ 0

FAIR VALUE DISCLOSURES - Summar

FAIR VALUE DISCLOSURES - Summary of Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable, Face Value	$ 271,815	$ 273,811
Preferred equity investment, Face Value	31,608	29,643
Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, Face Value	700,000	700,000
Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, Face Value	178,017	177,850
Carrying Amount [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	272,250	270,184
Preferred equity investments	31,958	29,993
Carrying Amount [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	686,336	685,704
Carrying Amount [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	175,045	174,846
Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	279,112	274,628
Preferred equity investments	33,719	30,838
Fair Value [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	697,250	718,500
Fair Value [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 169,579	$ 165,296

FAIR VALUE DISCLOSURES - Schedu

FAIR VALUE DISCLOSURES - Schedule of Inputs used for Carrying Amounts which do not Approximate Fair Value with Valuation Methods (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 279,112	$ 274,628
Preferred equity investments	33,719	30,838
Total [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	697,250	718,500
Total [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	169,579	$ 165,296
Recurring [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Recurring [Member] | Level 1 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring [Member] | Level 1 [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Recurring [Member] | Level 2 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	697,250
Recurring [Member] | Level 2 [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	279,112
Preferred equity investments	33,719
Recurring [Member] | Level 3 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring [Member] | Level 3 [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	169,579
Recurring [Member] | Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	279,112
Preferred equity investments	33,719
Recurring [Member] | Total [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	697,250
Recurring [Member] | Total [Member] | Mortgage indebtedness [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 169,579

FAIR VALUE DISCLOSURES - Sche51

FAIR VALUE DISCLOSURES - Schedule of Amounts Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	$ 3,508	$ 7,087
Financial liability	1,989	1,468
Recurring [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration asset	0
Contingent consideration liability	0
Recurring [Member] | Level 1 [Member] | Interest Rate Cap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	0
Recurring [Member] | Level 1 [Member] | Cross Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	0
Recurring [Member] | Level 1 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liability	0
Recurring [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration asset	0
Contingent consideration liability	0
Recurring [Member] | Level 2 [Member] | Interest Rate Cap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	670
Recurring [Member] | Level 2 [Member] | Cross Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	2,838
Recurring [Member] | Level 2 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liability	1,989
Recurring [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration asset	350	$ 400
Contingent consideration liability	2,700
Recurring [Member] | Level 3 [Member] | Interest Rate Cap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	0
Recurring [Member] | Level 3 [Member] | Cross Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	0
Recurring [Member] | Level 3 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liability	0
Recurring [Member] | Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration asset	350
Contingent consideration liability	2,700
Recurring [Member] | Total [Member] | Interest Rate Cap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	670
Recurring [Member] | Total [Member] | Cross Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Asset	2,838
Recurring [Member] | Total [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liability	$ 1,989

FAIR VALUE DISCLOSURES - Narrat

FAIR VALUE DISCLOSURES - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)acquisition	Dec. 31, 2015USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Businesses Acquired | acquisition	4
Recurring [Member] | Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liability	$ 2,700	$ 2,700
Contingent consideration asset	$ 350	$ 400

EQUITY - Narrative (Details)

EQUITY - Narrative (Details) - USD ($)	Mar. 21, 2013	Mar. 31, 2016	Dec. 31, 2015
Equity [Line Items]
Preferred stock, shares issued (in shares)	5,800,000	5,750,000	5,750,000
Preferred stock, dividend rate, percentage	7.125%
Price per share (in dollars per share)	$ 25
Preferred stock, net proceeds from offering	$ 138,300,000
Preferred stock, dividends in arrears		$ 0
Redemption share price (in dollars per share)	$ 25
Convertible preferred stock, conversion price (in dollars per share)	$ 25
Convertible preferred stock, shares issued upon conversion (in shares)	1.7864
Shares issued as a result of restricted stock unit vestings (in shares)		100,000
Tax withholding obligations on behalf of employees		1,100,000
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01

EQUITY - Schedule of Cash Divid

EQUITY - Schedule of Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares	Feb. 03, 2016	Mar. 31, 2016	Mar. 31, 2015
Equity [Abstract]
Common dividends (in dollars per share)	$ 0.41	$ 0.41	$ 0.39

EQUITY - Summary of Accumulated

EQUITY - Summary of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ 1,007,424	$ 1,053,770
Foreign currency translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(2,006)		$ (1,433)
Unrealized losses on cash flow hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(7,392)		(5,900)
Total accumulated other comprehensive loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ (9,398)		$ (7,333)

EARNINGS PER COMMON SHARE - Sch

EARNINGS PER COMMON SHARE - Schedule of the Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator
Net (loss) income attributable to common stockholders	$ (18,272)	$ 16,889
Denominator
Basic weighted average common shares (in shares)	65,248,203	59,185,225
Dilutive restricted stock units (in shares)	0	374,028
Diluted weighted average common shares (in shares)	65,248,203	59,559,253
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.28)	$ 0.29
Diluted common share (in dollars per share)	$ (0.28)	$ 0.28

EARNINGS PER COMMON SHARE - Nar

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock	54,000	300

SUMMARIZED CONDENSED CONSOLID58

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Narrative (Details) $ in Thousands	Mar. 31, 2016USD ($)
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION [Abstract]
Notes outstanding	$ 1,398,010

SUMMARIZED CONDENSED CONSOLID59

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Balance Sheet (unaudited) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Assets
Real estate investments, net of accumulated depreciation	$ 1,923,773	$ 2,039,616
Loans receivable and other investments, net	297,508	300,177
Cash and cash equivalents	9,133	7,434	$ 4,171	$ 61,793
Restricted cash	8,773	9,813
Assets held for sale	75,450	0
Prepaid expenses, deferred financing costs and other assets, net	119,519	111,797
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	2,434,156	2,468,837
Liabilities
Mortgage notes, net	175,045	174,846
Revolving credit facility	198,000	255,000
Term loans, net	338,629	264,229
Senior unsecured notes, net	686,336	685,704
Liabilities held for sale	340	0
Accounts payable and accrued liabilities	28,308	35,182
Intercompany	0	0
Total liabilities	1,426,658	1,414,961
Total Sabra Health Care REIT, Inc. stockholders' equity	1,007,424	1,053,770
Noncontrolling interests	74	106
Total equity	1,007,498	1,053,876	932,154	941,823
Total liabilities and equity	2,434,156	2,468,837
Parent Company [Member]
Assets
Real estate investments, net of accumulated depreciation	119	48
Loans receivable and other investments, net	0	0
Cash and cash equivalents	3,789	2,548	1,805	58,799
Restricted cash	0	0
Assets held for sale	0
Prepaid expenses, deferred financing costs and other assets, net	2,568	2,047
Intercompany	449,851	489,763
Investment in subsidiaries	561,125	568,841
Total assets	1,017,452	1,063,247
Liabilities
Mortgage notes, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Liabilities held for sale	0
Accounts payable and accrued liabilities	10,028	9,477
Intercompany	0	0
Total liabilities	10,028	9,477
Total Sabra Health Care REIT, Inc. stockholders' equity	1,007,424	1,053,770
Noncontrolling interests	0	0
Total equity	1,007,424	1,053,770
Total liabilities and equity	1,017,452	1,063,247
Issuers [Member]
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Assets held for sale	0
Prepaid expenses, deferred financing costs and other assets, net	12,940	13,384
Intercompany	890,493	918,209
Investment in subsidiaries	796,160	792,065
Total assets	1,699,593	1,723,658
Liabilities
Mortgage notes, net	0	0
Revolving credit facility	198,000	255,000
Term loans, net	243,372	200,000
Senior unsecured notes, net	686,336	685,704
Liabilities held for sale	0
Accounts payable and accrued liabilities	10,760	14,113
Intercompany	0	0
Total liabilities	1,138,468	1,154,817
Total Sabra Health Care REIT, Inc. stockholders' equity	561,125	568,841
Noncontrolling interests	0	0
Total equity	561,125	568,841
Total liabilities and equity	1,699,593	1,723,658
Combined Guarantor Subsidiaries [Member]
Assets
Real estate investments, net of accumulated depreciation	1,701,093	1,816,813
Loans receivable and other investments, net	299,675	302,282
Cash and cash equivalents	1,726	1,008	0	0
Restricted cash	128	1,618
Assets held for sale	75,450
Prepaid expenses, deferred financing costs and other assets, net	96,733	89,590
Intercompany	0	0
Investment in subsidiaries	56,849	55,439
Total assets	2,231,654	2,266,750
Liabilities
Mortgage notes, net	0	0
Revolving credit facility	0	0
Term loans, net	95,257	64,229
Senior unsecured notes, net	0	0
Liabilities held for sale	340
Accounts payable and accrued liabilities	8,597	11,254
Intercompany	1,323,532	1,391,115
Total liabilities	1,427,726	1,466,598
Total Sabra Health Care REIT, Inc. stockholders' equity	803,928	800,152
Noncontrolling interests	0	0
Total equity	803,928	800,152
Total liabilities and equity	2,231,654	2,266,750
Combined Non-Guarantor Subsidiaries [Member]
Assets
Real estate investments, net of accumulated depreciation	222,561	222,755
Loans receivable and other investments, net	0	0
Cash and cash equivalents	3,618	3,878	2,366	2,994
Restricted cash	8,645	8,195
Assets held for sale	0
Prepaid expenses, deferred financing costs and other assets, net	10,549	9,522
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	245,373	244,350
Liabilities
Mortgage notes, net	175,045	174,846
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Liabilities held for sale	0
Accounts payable and accrued liabilities	1,194	2,084
Intercompany	16,812	16,857
Total liabilities	193,051	193,787
Total Sabra Health Care REIT, Inc. stockholders' equity	52,248	50,457
Noncontrolling interests	74	106
Total equity	52,322	50,563
Total liabilities and equity	245,373	244,350
Elimination [Member]
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	(2,167)	(2,105)
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash	0	0
Assets held for sale	0
Prepaid expenses, deferred financing costs and other assets, net	(3,271)	(2,746)
Intercompany	(1,340,344)	(1,407,972)
Investment in subsidiaries	(1,414,134)	(1,416,345)
Total assets	(2,759,916)	(2,829,168)
Liabilities
Mortgage notes, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Liabilities held for sale	0
Accounts payable and accrued liabilities	(2,271)	(1,746)
Intercompany	(1,340,344)	(1,407,972)
Total liabilities	(1,342,615)	(1,409,718)
Total Sabra Health Care REIT, Inc. stockholders' equity	(1,417,301)	(1,419,450)
Noncontrolling interests	0	0
Total equity	(1,417,301)	(1,419,450)
Total liabilities and equity	$ (2,759,916)	$ (2,829,168)

SUMMARIZED CONDENSED CONSOLID60

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Income (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Rental income	$ 55,312	$ 49,505
Interest and other income	5,332	5,385
Resident fees and services	1,915	682
Total revenues	62,559	55,572
Expenses:
Depreciation and amortization	17,766	14,150
Interest	16,918	13,880
Operating expenses	1,412	498
General and administrative	4,714	6,361
Provision for doubtful accounts and loan losses	2,523	1,144
Impairment of real estate	29,811	0
Total expenses	73,144	36,033
Other income (expense):
Loss on extinguishment of debt	(556)	0
Other income (loss)	0	(100)
Net loss on sale of real estate	(4,602)	0
Total other income (expense)	(5,158)	(100)
Income in subsidiary	0	0
Net (loss) income	(15,743)	19,439
Net loss attributable to noncontrolling interests	32	11
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(15,711)	19,450
Preferred stock dividends	(2,561)	(2,561)
Net (loss) income attributable to common stockholders	$ (18,272)	$ 16,889
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.28)	$ 0.29
Diluted common share (in dollars per share)	$ (0.28)	$ 0.28
Weighted-average number of common shares outstanding, basic (in shares)	65,248,203	59,185,225
Weighted-average number of common shares outstanding, diluted (in shares)	65,248,203	59,559,253
Parent Company [Member]
Revenues:
Rental income	$ 0	$ 0
Interest and other income	0	1
Resident fees and services	0	0
Total revenues	0	1
Expenses:
Depreciation and amortization	183	13
Interest	0	0
Operating expenses	0	0
General and administrative	4,473	5,902
Provision for doubtful accounts and loan losses	233	(464)
Impairment of real estate	0
Total expenses	4,889	5,451
Other income (expense):
Loss on extinguishment of debt	0
Other income (loss)	0	0
Net loss on sale of real estate	0
Total other income (expense)	0	0
Income in subsidiary	(10,759)	24,900
Net (loss) income	(15,648)	19,450
Net loss attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(15,648)	19,450
Preferred stock dividends	(2,561)	(2,561)
Net (loss) income attributable to common stockholders	(18,209)	16,889
Issuers [Member]
Revenues:
Rental income	0	0
Interest and other income	119	0
Resident fees and services	0	0
Total revenues	119	0
Expenses:
Depreciation and amortization	0	0
Interest	14,302	12,550
Operating expenses	0	0
General and administrative	10	0
Provision for doubtful accounts and loan losses	0	0
Impairment of real estate	0
Total expenses	14,312	12,550
Other income (expense):
Loss on extinguishment of debt	(468)
Other income (loss)	500	0
Net loss on sale of real estate	0
Total other income (expense)	32	0
Income in subsidiary	3,402	37,450
Net (loss) income	(10,759)	24,900
Net loss attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(10,759)	24,900
Preferred stock dividends	0	0
Net (loss) income attributable to common stockholders	(10,759)	24,900
Combined Guarantor Subsidiaries [Member]
Revenues:
Rental income	48,858	44,601
Interest and other income	5,410	5,384
Resident fees and services	1,344	0
Total revenues	55,612	49,985
Expenses:
Depreciation and amortization	15,509	12,702
Interest	869	0
Operating expenses	967	0
General and administrative	169	415
Provision for doubtful accounts and loan losses	2,290	1,608
Impairment of real estate	29,811
Total expenses	49,615	14,725
Other income (expense):
Loss on extinguishment of debt	(88)
Other income (loss)	(450)	(100)
Net loss on sale of real estate	(4,602)
Total other income (expense)	(5,140)	(100)
Income in subsidiary	0	1,395
Net (loss) income	857	36,555
Net loss attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.	857	36,555
Preferred stock dividends	0	0
Net (loss) income attributable to common stockholders	857	36,555
Combined Non-Guarantor Subsidiaries [Member]
Revenues:
Rental income	6,690	4,904
Interest and other income	(15)	0
Resident fees and services	571	682
Total revenues	7,246	5,586
Expenses:
Depreciation and amortization	2,074	1,435
Interest	1,866	1,330
Operating expenses	681	498
General and administrative	62	44
Provision for doubtful accounts and loan losses	0	0
Impairment of real estate	0
Total expenses	4,683	3,307
Other income (expense):
Loss on extinguishment of debt	0
Other income (loss)	(50)	0
Net loss on sale of real estate	0
Total other income (expense)	(50)	0
Income in subsidiary	0	0
Net (loss) income	2,513	2,279
Net loss attributable to noncontrolling interests	32	11
Net (loss) income attributable to Sabra Health Care REIT, Inc.	2,545	2,290
Preferred stock dividends	0	0
Net (loss) income attributable to common stockholders	2,545	2,290
Elimination [Member]
Revenues:
Rental income	(236)	0
Interest and other income	(182)	0
Resident fees and services	0	0
Total revenues	(418)	0
Expenses:
Depreciation and amortization	0	0
Interest	(119)	0
Operating expenses	(236)	0
General and administrative	0	0
Provision for doubtful accounts and loan losses	0	0
Impairment of real estate	0
Total expenses	(355)	0
Other income (expense):
Loss on extinguishment of debt	0
Other income (loss)	0	0
Net loss on sale of real estate	0
Total other income (expense)	0	0
Income in subsidiary	7,357	(63,745)
Net (loss) income	7,294	(63,745)
Net loss attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.	7,294	(63,745)
Preferred stock dividends	0	0
Net (loss) income attributable to common stockholders	$ 7,294	$ (63,745)

SUMMARIZED CONDENSED CONSOLID61

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Comprehensive Income (unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	$ (15,743)	$ 19,439
Other comprehensive income (loss):
Foreign currency translation	(573)	0
Unrealized loss on cash flow hedges	(1,492)	(1,545)
Total other comprehensive loss	(2,065)	(1,545)
Comprehensive (loss) income	(17,808)	17,894
Comprehensive loss attributable to noncontrolling interest	32	11
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(17,776)	17,905
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	(15,648)	19,450
Other comprehensive income (loss):
Foreign currency translation	0
Unrealized loss on cash flow hedges	0	0
Total other comprehensive loss	0	0
Comprehensive (loss) income	(15,648)	19,450
Comprehensive loss attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(15,648)	19,450
Issuers [Member]
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	(10,759)	24,900
Other comprehensive income (loss):
Foreign currency translation	(2,643)
Unrealized loss on cash flow hedges	(1,492)	(1,545)
Total other comprehensive loss	(4,135)	(1,545)
Comprehensive (loss) income	(14,894)	23,355
Comprehensive loss attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(14,894)	23,355
Combined Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	857	36,555
Other comprehensive income (loss):
Foreign currency translation	1,632
Unrealized loss on cash flow hedges	0	0
Total other comprehensive loss	1,632	0
Comprehensive (loss) income	2,489	36,555
Comprehensive loss attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	2,489	36,555
Combined Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	2,513	2,279
Other comprehensive income (loss):
Foreign currency translation	438
Unrealized loss on cash flow hedges	0	0
Total other comprehensive loss	438	0
Comprehensive (loss) income	2,951	2,279
Comprehensive loss attributable to noncontrolling interest	32	11
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	2,983	2,290
Elimination [Member]
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	7,294	(63,745)
Other comprehensive income (loss):
Foreign currency translation	0
Unrealized loss on cash flow hedges	0	0
Total other comprehensive loss	0	0
Comprehensive (loss) income	7,294	(63,745)
Comprehensive loss attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	$ 7,294	$ (63,745)

SUMMARIZED CONDENSED CONSOLID62

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Cash Flows (unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	$ 24,726	$ 24,701
Cash flows from investing activities:
Origination and fundings of loans receivable	(5,850)	(7,303)
Origination and fundings of preferred equity investments	(984)	(311)
Additions to real estate	(474)	(675)
Repayment of loans/notes receivable	8,874	2,052
Investment in subsidiary	0	0
Net proceeds from the sale of real estate	398	0
Distribution from subsidiary	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	1,964	(6,237)
Cash flows from financing activities:
Net repayments from prior revolving credit facility	(57,000)	(42,000)
Proceeds from term loans	69,360	0
Principal payments on mortgage notes	(1,022)	(697)
Payments of deferred financing costs	(5,885)	(130)
Issuance of common stock	(1,274)	(7,587)
Dividends paid on common and preferred stock	(29,301)	(25,672)
Contribution from parent	0	0
Distribution to parent	0	0
Intercompany financing	0	0
Net cash (used in) provided by financing activities	(25,122)	(76,086)
Net increase (decrease) in cash and cash equivalents	1,568	(57,622)
Effect of foreign currency translation on cash and cash equivalents	131	0
Cash and cash equivalents, beginning of period	7,434	61,793
Cash and cash equivalents, end of period	9,133	4,171
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	21,718	23,502
Cash flows from investing activities:
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	(74)	(3)
Repayment of loans/notes receivable	0	0
Investment in subsidiary	(200)	(414)
Net proceeds from the sale of real estate	0
Distribution from subsidiary	2,025	1,355
Intercompany financing	8,347	(48,175)
Net cash provided by (used in) investing activities	10,098	(47,237)
Cash flows from financing activities:
Net repayments from prior revolving credit facility	0	0
Proceeds from term loans	0
Principal payments on mortgage notes	0	0
Payments of deferred financing costs	0	0
Issuance of common stock	(1,274)	(7,587)
Dividends paid on common and preferred stock	(29,301)	(25,672)
Contribution from parent	0	0
Distribution to parent	0	0
Intercompany financing	0	0
Net cash (used in) provided by financing activities	(30,575)	(33,259)
Net increase (decrease) in cash and cash equivalents	1,241	(56,994)
Effect of foreign currency translation on cash and cash equivalents	0
Cash and cash equivalents, beginning of period	2,548	58,799
Cash and cash equivalents, end of period	3,789	1,805
Issuers [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0
Cash flows from investing activities:
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	0
Repayment of loans/notes receivable	0	0
Investment in subsidiary	(200)	(414)
Net proceeds from the sale of real estate	0
Distribution from subsidiary	2,025	1,355
Intercompany financing	25,621	(6,063)
Net cash provided by (used in) investing activities	27,446	(5,122)
Cash flows from financing activities:
Net repayments from prior revolving credit facility	(57,000)	(42,000)
Proceeds from term loans	45,000
Principal payments on mortgage notes	0	0
Payments of deferred financing costs	(5,274)	(112)
Issuance of common stock	0	0
Dividends paid on common and preferred stock	0	0
Contribution from parent	200	414
Distribution to parent	(2,025)	(1,355)
Intercompany financing	(8,347)	48,175
Net cash (used in) provided by financing activities	(27,446)	5,122
Net increase (decrease) in cash and cash equivalents	0	0
Effect of foreign currency translation on cash and cash equivalents	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Combined Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	439	0
Cash flows from investing activities:
Origination and fundings of loans receivable	(5,850)	(7,303)
Origination and fundings of preferred equity investments	(984)	(311)
Additions to real estate	(400)	(501)
Repayment of loans/notes receivable	8,874	$ 2,052
Investment in subsidiary	0
Net proceeds from the sale of real estate	398
Distribution from subsidiary	0	$ 0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	2,038	(6,063)
Cash flows from financing activities:
Net repayments from prior revolving credit facility	0	0
Proceeds from term loans	24,360
Principal payments on mortgage notes	0	0
Payments of deferred financing costs	(611)	0
Issuance of common stock	0	0
Dividends paid on common and preferred stock	0	0
Contribution from parent	0	0
Distribution to parent	0	0
Intercompany financing	(25,621)	6,063
Net cash (used in) provided by financing activities	(1,872)	6,063
Net increase (decrease) in cash and cash equivalents	605	0
Effect of foreign currency translation on cash and cash equivalents	113
Cash and cash equivalents, beginning of period	1,008	0
Cash and cash equivalents, end of period	1,726	0
Combined Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	2,569	1,199
Cash flows from investing activities:
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	(171)
Repayment of loans/notes receivable	0	0
Investment in subsidiary	0	0
Net proceeds from the sale of real estate	0
Distribution from subsidiary	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	0	(171)
Cash flows from financing activities:
Net repayments from prior revolving credit facility	0	0
Proceeds from term loans	0
Principal payments on mortgage notes	(1,022)	(697)
Payments of deferred financing costs	0	(18)
Issuance of common stock	0	0
Dividends paid on common and preferred stock	0	0
Contribution from parent	200	414
Distribution to parent	(2,025)	(1,355)
Intercompany financing	0	0
Net cash (used in) provided by financing activities	(2,847)	(1,656)
Net increase (decrease) in cash and cash equivalents	(278)	(628)
Effect of foreign currency translation on cash and cash equivalents	18
Cash and cash equivalents, beginning of period	3,878	2,994
Cash and cash equivalents, end of period	3,618	2,366
Elimination [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0
Cash flows from investing activities:
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	0
Repayment of loans/notes receivable	0	0
Investment in subsidiary	400	828
Net proceeds from the sale of real estate	0
Distribution from subsidiary	(4,050)	(2,710)
Intercompany financing	(33,968)	54,238
Net cash provided by (used in) investing activities	(37,618)	52,356
Cash flows from financing activities:
Net repayments from prior revolving credit facility	0	0
Proceeds from term loans	0
Principal payments on mortgage notes	0	0
Payments of deferred financing costs	0	0
Issuance of common stock	0	0
Dividends paid on common and preferred stock	0	0
Contribution from parent	(400)	(828)
Distribution to parent	4,050	2,710
Intercompany financing	33,968	(54,238)
Net cash (used in) provided by financing activities	37,618	(52,356)
Net increase (decrease) in cash and cash equivalents	0	0
Effect of foreign currency translation on cash and cash equivalents	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	$ 0	$ 0

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	May. 02, 2016	Apr. 01, 2016	Feb. 03, 2016	Mar. 31, 2016	Mar. 31, 2015
Subsequent Event [Line Items]
Common dividends, declared (in dollars per share)			$ 0.41	$ 0.41	$ 0.39
Subsequent Event [Member] | Forest Park Medical Center At Frisco, LLC [Member] | Discontinued Operations, Disposed of by Sale [Member]
Subsequent Event [Line Items]
Consideration		$ 96.3
Capital lease obligations		7.3
Net cash proceeds		86.6
Additional cash expected to receive		3.5
Impairment charge on investment		29.8
Loan loss reserve in period		3.1
Guarantees		$ 21.3
Subsequent Event [Member] | Dividend Declared [Member]
Subsequent Event [Line Items]
Common dividends, declared (in dollars per share)	$ 0.42
Preferred stock dividends, declared (in dollars per share)	$ 0.4453125